var title_f25_53_26448="Hemozoin in monocyte";
var content_f25_53_26448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malarial pigment (hemozoin) in a monocyte",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Malarial pigment in a monocyte - Peripheral blood smear taken from a patient presenting with signs and symptoms suggestive of cerebral malaria due to infection with P. falciparum. It shows a monocyte with several dark, irregular, pigmented inclusions (arrows), representing hemoglobin from the patient's red cells incompletely degraded by the parasite (malarial pigment, hemozoin), released into the circulation during schizony, and phagocytosed by cells of the monocyte-macrophage system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26448=[""].join("\n");
var outline_f25_53_26448=null;
var title_f25_53_26449="Reflux esophagitis";
var content_f25_53_26449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophagitis and patulous gastroesophageal junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 7-year-old with intermittent burning in her abdomen that was not responsive to routine pharmacologic therapy. Endoscopy demonstrates mild esophagitis with slight erythema at patulous gastroesophageal junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Murray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26449=[""].join("\n");
var outline_f25_53_26449=null;
var title_f25_53_26450="Upper airway obstruction";
var content_f25_53_26450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73686%7EPULM%2F76811%7EPULM%2F76796%7EPULM%2F80922%7EPULM%2F74178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73686%7EPULM%2F76811%7EPULM%2F76796%7EPULM%2F80922%7EPULM%2F74178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Importance of the degree of upper airway obstrucion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Volume (as liters [L] from total lung capacity [TLC]) is plotted against inspiratory and expiratory flows. The blue line (C) is the control effort; the numbers refer to the orifice diameters. Lesions must narrow the tracheal lumen to less than&nbsp;8 mm before abnormalities can be detected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Miller RD, Hyatt RE, Mayo Clin Proc 1969; 44:145.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Flow-volume loops in upper airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 151px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel shows fixed upper airway obstruction with flow limitation and flattening of both the inspiratory and expiratory limbs of the flow-volume loop. Middle panel shows dynamic (or variable, nonfixed) extrathoracic obstruction with flow limitation and flattening of the inspiratory limb of the loop. Right panel shows dynamic (or variable, nonfixed) intrathoracic obstruction with flow limitation and flattening of the expiratory limb of the loop.",
"    <div class=\"footnotes\">",
"     TLC: total lung capacity; RV: residual volume.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Stoller JK, Cleve Clin J Med 1992; 59:75.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Functional mainstem bronchial obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maximal expiratory and inspiratory flow-volume loops before (inner green loop) and after (outer blue loop) surgery in a patient with mainstem bronchial obstruction. The diameter of the orifice at the site of maximal obstruction both before and after treatment is shown in relation to the corresponding flow-volume loop. Note the relatively parallel rightward shift of the descending limb of the maximal expiratory flow-volume curve after treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Partially occluded right mainstem bronchus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 193px; height: 149px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maximal expiratory and inspiratory flow-volume loops before (green, 6mm) and after (blue, 9mm) laser treatment in a patient with a right mainstem bronchial obstruction in addition to complete obstruction of the left mainstem bronchus. The diameter of the orifice at the site of maximal obstruction of the mainstem bronchus both before and after treatment is shown in relation to the corresponding flow-volume loop. Note the relatively parallel rightward shift of the descending limb of the maximal expiratory flow-volume curve after treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow volume loop in mainstem bronchial obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 179px; height: 173px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maximum flow-volume curves of patient before insertion of a stent in a narrowed left main bronchus. Both an end-inspiratory tail and a biphasic spirogram are seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26450=[""].join("\n");
var outline_f25_53_26450=null;
var title_f25_53_26451="MRI urethral diverticulum3";
var content_f25_53_26451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of female urethral diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T1 axial contrast enhanced MR images shows a diverticulum (arrows) wrapped around the urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26451=[""].join("\n");
var outline_f25_53_26451=null;
var title_f25_53_26452="Vitamin B3 (niacin): Patient drug information";
var content_f25_53_26452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin B3 (niacin): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6951?source=see_link\">",
"     see \"Vitamin B3 (niacin): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/2/5158?source=see_link\">",
"     see \"Vitamin B3 (niacin): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Niacin-Time&reg; [OTC];",
"     </li>",
"     <li>",
"      Niacor&reg;;",
"     </li>",
"     <li>",
"      Niaspan&reg;;",
"     </li>",
"     <li>",
"      Slo-Niacin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Niaspan&reg;;",
"     </li>",
"     <li>",
"      Niaspan&reg; FCT;",
"     </li>",
"     <li>",
"      Niodan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This vitamin is used to treat niacin deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to niacin, niacinamide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Liver disease or ulcer disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol use may cause more flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698093",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Taking aspirin or ibuprofen 30 minutes before taking this drug may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if you are taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid hot drinks when it is time to take this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11399 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26452=[""].join("\n");
var outline_f25_53_26452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027880\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027879\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027884\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027885\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027887\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027882\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027883\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027888\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027889\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/50/6951?source=related_link\">",
"      Vitamin B3 (niacin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/2/5158?source=related_link\">",
"      Vitamin B3 (niacin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_53_26453="Sigmoid volvulus";
var content_f25_53_26453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sigmoid volvulus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26453/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26453/contributors\">",
"     Richard A Hodin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26453/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26453/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26453/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26453/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/53/26453/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volvulus refers to torsion of a segment of the alimentary tract, which often leads to bowel obstruction. The most common sites of volvulus are the sigmoid colon and cecum. Volvulus of other portions of the alimentary tract, such as the stomach, gallbladder, small bowel, splenic flexure, and transverse colon, are rare.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of sigmoid volvulus will be reviewed here. Cecal volvulus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8663?source=see_link\">",
"     \"Cecal volvulus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volvulus of the sigmoid colon represents approximately 40 to 70 percent of colonic volvulus depending upon the age of patients and the geographic location of the series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In one report of 137 patients with colonic volvulus seen at the Mayo Clinic, for example, the following colonic segments were involved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cecum &ndash; 52 percent",
"     </li>",
"     <li>",
"      Sigmoid &ndash; 43 percent",
"     </li>",
"     <li>",
"      Transverse colon &ndash; 3 percent",
"     </li>",
"     <li>",
"      Splenic flexure &ndash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The precise incidence of sigmoid volvulus in the population is not well-established, and its prevalence among patients who present with acute intestinal obstruction varies geographically. In the United States, sigmoid volvulus is a relatively uncommon cause of intestinal obstruction representing fewer than 10 percent of cases in most series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, for unclear reasons, the prevalence is much higher in other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. As an example, sigmoid volvulus was responsible in 80 percent of cases of intestinal obstruction from the Bolivian and Peruvian Andes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/5\">",
"     5",
"    </a>",
"    ], and 50 percent of cases of large bowel obstruction in Nigeria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/9\">",
"     9",
"    </a>",
"    ]. The incidence may also be increased in Brazil, where it may be a complication of megacolon caused by Chagas disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=see_link\">",
"     \"Pathology and pathogenesis of Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic features predisposing to sigmoid volvulus include a redundant sigmoid colon that has a narrow mesenteric attachment. Although a number of risk factors associated with sigmoid volvulus can be explained by these anatomic considerations, the precise pathogenesis underlying sigmoid torsion has not been well-established.",
"   </p>",
"   <p>",
"    In most series, sigmoid volvulus occurred in elderly patients, often those who are institutionalized and debilitated with neurologic and psychiatric conditions such as Parkinson disease and schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In a report from England of 40 patients, the average age was 72; 40 percent lived in nursing homes or institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/12\">",
"     12",
"    </a>",
"    ]. By contrast, the mean age was 58 in a report from Turkey of 688 patients with sigmoid volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons why sigmoid volvulus is more common with advancing age are not well-understood. Lengthening of the sigmoid colon and its mesentery is not a feature of normal aging. One possible explanation is colonic dysmotility, which could predispose to torsion of the sigmoid colon. Support for an underlying motility problem was provided in one series of 58 patients with colonic volvulus in whom a large bowel motility disturbance was observed in 9 of 20 patients (45 percent) following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/2\">",
"     2",
"    </a>",
"    ]. Presumably, motility disorders were also present in some of these patients prior to surgery. In addition, prolonged transit of stool through the sigmoid colon and rectum has been observed in frail elderly patients who are constipated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sigmoid volvulus can also occur in younger patients and in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/15-19\">",
"     15-19",
"    </a>",
"    ], in whom the diagnosis may be delayed due to the atypical age of presentation and the intermittent nature of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/20\">",
"     20",
"    </a>",
"    ]. In children, sigmoid volvulus can be the initial presenting feature of Hirschsprung's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/21\">",
"     21",
"    </a>",
"    ]. An aganglionic segment below the sigmoid colon and a freely mobile mesosigmoid may be responsible in this setting.",
"   </p>",
"   <p>",
"    Sigmoid volvulus has occurred in a number of other settings including Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/22\">",
"     22",
"    </a>",
"    ], pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], Chagas disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/7\">",
"     7",
"    </a>",
"    ], and colonic hypertrophy associated with a high fiber diet [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/25\">",
"     25",
"    </a>",
"    ]. In some series, the disease was more common in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/4\">",
"     4",
"    </a>",
"    ], but others have reported equal gender frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/12,26\">",
"     12,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variant of sigmoid volvulus (ileosigmoid knotting) occurs when the ileum wraps itself around the sigmoid. The most common type occurs when the ileum encircles the sigmoid colon in a clockwise manner. Laxity of the ileal and sigmoid mesentery may predispose to this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with sigmoid volvulus present with abdominal pain, nausea, abdominal distension, and constipation; vomiting is less common. However, some patients (particularly younger patients) may have a more insidious presentation with recurrent attacks of abdominal pain, with resolution presumably due to spontaneous detorsion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/15\">",
"     15",
"    </a>",
"    ]. The disease may not be as apparent in the frail elderly or in patients with neurologic diseases who are unable to express their complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective series from Turkey described clinical features in 859 patients with sigmoid volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/31\">",
"     31",
"    </a>",
"    ]. The mean age of the patients was 58 years, 83 percent were men and 9 percent had a prior history of sigmoid volvulus. The most common clinical features were abdominal pain and tenderness (99 percent), distention (96 percent), and obstipation (92 percent). Plain abdominal X-rays revealed evidence of sigmoid volvulus in 65 percent of the patients. CT scan, MRI, and sigmoidoscopy were used to establish the diagnosis in other patients.",
"   </p>",
"   <p>",
"    Compromise of the blood supply to the sigmoid colon can lead to gangrene with resulting peritonitis and sepsis. Fortunately, the majority of patients come to medical attention prior to the development of gangrene. As an example, in one series of 54 patients with sigmoid volvulus, only four (7 percent) presented with gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/32\">",
"     32",
"    </a>",
"    ]. However, gangrene may not be suspected in its early stages based upon the physical examination and laboratory findings, and can develop rapidly in patients in whom the volvulus is not corrected.",
"   </p>",
"   <p>",
"    The diagnosis is often suspected based upon the clinical presentation and physical examination. The pain associated with sigmoid volvulus is usually continuous and severe, with a superimposed colicky component occurring during peristalsis. The abdomen is usually distended and tympanitic.",
"   </p>",
"   <p>",
"    A plain film of the abdomen can establish the diagnosis in approximately 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/11,31\">",
"     11,31",
"    </a>",
"    ]. The distended sigmoid colon appears as an ahaustral collection of gas (sometimes referred to as a \"bent inner tube\") that extends from the pelvis to the right upper quadrant as high as the diaphragm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67675 \" href=\"UTD.htm?26/39/27254\">",
"     image 1",
"    </a>",
"    ). Distended large bowel proximal to the sigmoid and air-fluid levels in the small bowel are often present. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema using water-soluble contrast may be helpful in uncertain cases.",
"   </p>",
"   <p>",
"    The diagnosis can also be made by CT scan. Typical findings include a whirl pattern, caused by the dilated sigmoid colon around its mesocolon and vessels, and a bird-beak appearance of the afferent and efferent colonic segments [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/33\">",
"     33",
"    </a>",
"    ]. These classic imaging features are not uniformly seen, and other CT findings have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment of sigmoid volvulus are to prevent the development of gangrene and to address the anatomic abnormality that led to the volvulus. An effective way to restore the blood supply to the colon is to detorse the volvulus, which can be accomplished by advancing a flexible or rigid sigmoidoscope through the twisted segment. An additional advantage of sigmoidoscopy is assessment of the viability of the colon. The procedure should be immediately stopped to prevent bowel perforation if the mucosa appears gangrenous. Furthermore, sigmoidoscopy should not be performed in patients who are likely to have already developed intestinal gangrene (such as those with sepsis, fever, or peritonitis).",
"   </p>",
"   <p>",
"    The area of twisting is usually evident within 25 cm of the anal verge. A spiral, sphincter-like area of mucosa will be encountered at the area of torsion. Gentle pressure with minimal insufflation will permit advancement of the sigmoidoscope, causing straightening of the sigmoid colon. A dilated segment proximal to the sigmoid colon filled with gas and stool or a sudden expulsion of gas indicates successful reduction of the volvulus. Gas and fluid should be suctioned prior to withdrawal of the instrument. The mucosa should be carefully inspected for evidence of bowel ischemia. Counterclockwise twisting of the sigmoidoscope during withdrawal is probably not necessary since straightening of the sigmoid colon occurs during advancement.",
"   </p>",
"   <p>",
"    Many endoscopists choose to leave a rectal tube in place with its proximal end beyond the area of twisting. The advantage of a rectal tube compared to sigmoidoscopic decompression without a rectal tube has not been well-established. However, a rectal tube may lessen colonic distension and reduce the chance of recurrent volvulus in the acute setting.",
"   </p>",
"   <p>",
"    Reduction of the sigmoid volvulus using this technique has been successful in 85 to 95 percent of cases in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/11,35\">",
"     11,35",
"    </a>",
"    ]. The major problem is recurrence in up to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/12,36\">",
"     12,36",
"    </a>",
"    ]. The time to recurrence can vary from hours to weeks; as a result, definitive treatment soon after sigmoidoscopic reduction is advised. Initial sigmoidoscopic reduction of the volvulus converts an emergency procedure into a semiurgent procedure with ample time for bowel preparation and preoperative care. Although surgical resection without decompression has been used at some centers with acceptable outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/37\">",
"     37",
"    </a>",
"    ], we favor preoperative decompression whenever feasible.",
"   </p>",
"   <p>",
"    The surgical approaches to prevent recurrent volvulus include mesosigmoidopexy and resection with primary anastomosis or a Hartmann's procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/1,13,32,37,38\">",
"     1,13,32,37,38",
"    </a>",
"    ]. Sigmoid resection with primary anastomosis has been associated with the greatest success in patients who have not developed gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/1,13,38\">",
"     1,13,38",
"    </a>",
"    ]. Surgery can usually be performed through a small left lower quadrant transverse incision, since the elongated bowel and mesentery easily protrude outside of the abdomen. Percutaneous endoscopic colostomy has been described in case series but has been associated with significant morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality related to sigmoid volvulus is highest (11 to 60 percent in various series) in patients who have developed gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/1,11,36-38\">",
"     1,11,36-38",
"    </a>",
"    ]. In contrast, the mortality is less than 10 percent in patients treated by surgical resection who have not developed gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These numbers compare to the unlikely occurrence of death in patients without gangrene following successful sigmoidoscopic reduction. This observation has led some authorities to argue that surgery should be reserved for patients in whom sigmoidoscopic reduction is unsuccessful since as many as 40 to 50 percent of these patients will not have a recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26453/abstract/11\">",
"     11",
"    </a>",
"    ]. However, no reliable criteria can predict recurrence, and some patients may have already developed gangrene unsuspected on sigmoidoscopy. Thus, this conservative approach should be reserved for patients in whom definitive surgical therapy is considered to be associated with prohibitive risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volvulus refers to torsion of a segment of the alimentary tract, which often leads to bowel obstruction. The most common sites of volvulus are the sigmoid colon and cecum.",
"     </li>",
"     <li>",
"      Anatomic features predisposing to sigmoid volvulus include a redundant sigmoid colon that has a narrow mesenteric attachment but the precise pathogenesis underlying sigmoid torsion has not been well established. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with sigmoid volvulus present with abdominal pain, nausea, abdominal distension, and constipation; vomiting is less common. However, some patients (particularly younger patients) may have a more insidious presentation with recurrent attacks of abdominal pain, with resolution presumably due to spontaneous detorsion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A plain film of the abdomen can establish the diagnosis in approximately 60 percent of patients (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67675 \" href=\"UTD.htm?26/39/27254\">",
"       image 1",
"      </a>",
"      ). The diagnosis can also be made by CT scan. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment of sigmoid volvulus are to prevent the development of gangrene and to address the anatomic abnormality that led to the volvulus. In patients who do not have clinical features suggestive of gangrene or perforation, we suggest flexible sigmoidoscopy in an attempt to detorse the twisted segment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Following successful detorsion, we suggest leaving a rectal tube in place (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Recurrent volvulus develops in about 50 to 60 percent of patients. As a result, we suggest surgery to prevent recurrence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally perform a mechanical bowel preparation and then a standard open laparotomy with sigmoid resection and primary anastomosis. Exceptions are patients in whom definitive surgical therapy is considered to be associated with prohibitive risks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/1\">",
"      Ballantyne GH, Brandner MD, Beart RW Jr, Ilstrup DM. Volvulus of the colon. Incidence and mortality. Ann Surg 1985; 202:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/2\">",
"      Friedman JD, Odland MD, Bubrick MP. Experience with colonic volvulus. Dis Colon Rectum 1989; 32:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/3\">",
"      Hiltunen KM, Syrj&auml; H, Matikainen M. Colonic volvulus. Diagnosis and results of treatment in 82 patients. Eur J Surg 1992; 158:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/4\">",
"      P&aring;hlman L, Enblad P, Rudberg C, Krog M. Volvulus of the colon. A review of 93 cases and current aspects of treatment. Acta Chir Scand 1989; 155:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/5\">",
"      Asbun HJ, Castellanos H, Balderrama B, et al. Sigmoid volvulus in the high altitude of the Andes. Review of 230 cases. Dis Colon Rectum 1992; 35:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/6\">",
"      Astini C, Falaschi CF, Mariam M, Desta A. The management of sigmoid volvulus: report of 39 cases. Ital J Surg Sci 1988; 18:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/7\">",
"      Gama AH, Haddad J, Simonsen O, et al. Volvulus of the sigmoid colon in Brazil: a report of 230 cases. Dis Colon Rectum 1976; 19:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/8\">",
"      Schagen van Leeuwen JH. Sigmoid volvulus in a West African population. Dis Colon Rectum 1985; 28:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/9\">",
"      Udezue NO. Sigmoid volvulus in Kaduna, Nigeria. Dis Colon Rectum 1990; 33:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/10\">",
"      Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J Am Geriatr Soc 1987; 35:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/11\">",
"      Mangiante EC, Croce MA, Fabian TC, et al. Sigmoid volvulus. A four-decade experience. Am Surg 1989; 55:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/12\">",
"      Baker DM, Wardrop PJ, Burrell H, Hardcastle JD. The management of acute sigmoid volvulus in Nottingham. J R Coll Surg Edinb 1994; 39:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/13\">",
"      Oren D, Atamanalp SS, Aydinli B, et al. An algorithm for the management of sigmoid colon volvulus and the safety of primary resection: experience with 827 cases. Dis Colon Rectum 2007; 50:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/14\">",
"      Harari D, Gurwitz JH, Minaker KL. Constipation in the elderly. J Am Geriatr Soc 1993; 41:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/15\">",
"      Krupsky S, Halevy A, Orda R. Sigmoid volvulus in adolescence. J Clin Gastroenterol 1987; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/16\">",
"      Mellor MF, Drake DG. Colonic volvulus in children: value of barium enema for diagnosis and treatment in 14 children. AJR Am J Roentgenol 1994; 162:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/17\">",
"      Sroujieh AS, Farah GR, Jabaiti SK, et al. Volvulus of the sigmoid colon in Jordan. Dis Colon Rectum 1992; 35:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/18\">",
"      Atamanalp SS, Yildirgan MI, Ba��o��lu M, et al. Sigmoid colon volvulus in children: review of 19 cases. Pediatr Surg Int 2004; 20:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/19\">",
"      Ton MN, Ruzal-Shapiro C, Stolar C, Kazlow PG. Recurrent sigmoid volvulus in a sixteen-year-old boy: case report and review of the literature. J Pediatr Surg 2004; 39:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/20\">",
"      Northeast AD, Dennison AR, Lee EG. Sigmoid volvulus: new thoughts on the epidemiology. Dis Colon Rectum 1984; 27:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/21\">",
"      Sario��lu A, Tanyel FC, B&uuml;y&uuml;kpamuk&ccedil;u N, Hi&ccedil;s&ouml;nmez A. Colonic volvulus: a rare presentation of Hirschsprung's disease. J Pediatr Surg 1997; 32:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/22\">",
"      Lashner BA, Anastaplo SM, Kirsner JB. Sigmoid volvulus as a complication of ileal Crohn's disease. J Clin Gastroenterol 1989; 11:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/23\">",
"      Lord SA, Boswell WC, Hungerpiller JC. Sigmoid volvulus in pregnancy. Am Surg 1996; 62:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/24\">",
"      Alshawi JS. Recurrent sigmoid volvulus in pregnancy: report of a case and review of the literature. Dis Colon Rectum 2005; 48:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/25\">",
"      Taha SE, Suleiman SI. Volvulus of the sigmoid colon in the Gezira. Br J Surg 1980; 67:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/26\">",
"      Isbister WH. Large bowel volvulus. Int J Colorectal Dis 1996; 11:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/27\">",
"      Alver O, Oren D, Tireli M, et al. Ileosigmoid knotting in Turkey. Review of 68 cases. Dis Colon Rectum 1993; 36:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/28\">",
"      VerSteeg KR, Whitehead WA. Ileosigmoid knot. Arch Surg 1980; 115:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/29\">",
"      Machado NO. Ileosigmoid knot: a case report and literature review of 280 cases. Ann Saudi Med 2009; 29:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/30\">",
"      Avots-Avotins KV, Waugh DE. Colon volvulus and the geriatric patient. Surg Clin North Am 1982; 62:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/31\">",
"      Retraction. Clinical presentation and diagnosis of sigmoid volvulus: outcomes of 40-year and 859-patient experience. J Gastroenterol Hepatol 2009; 24:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/32\">",
"      Peoples JB, McCafferty JC, Scher KS. Operative therapy for sigmoid volvulus. Identification of risk factors affecting outcome. Dis Colon Rectum 1990; 33:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/33\">",
"      Catalano O. Computed tomographic appearance of sigmoid volvulus. Abdom Imaging 1996; 21:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/34\">",
"      Levsky JM, Den EI, DuBrow RA, et al. CT findings of sigmoid volvulus. AJR Am J Roentgenol 2010; 194:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/35\">",
"      Anderson JR, Lee D. The management of acute sigmoid volvulus. Br J Surg 1981; 68:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/36\">",
"      Brothers TE, Strodel WE, Eckhauser FE. Endoscopy in colonic volvulus. Ann Surg 1987; 206:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/37\">",
"      Kuzu MA, A��lar AK, Soran A, et al. Emergent resection for acute sigmoid volvulus: results of 106 consecutive cases. Dis Colon Rectum 2002; 45:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/38\">",
"      Bagarani M, Conde AS, Longo R, et al. Sigmoid volvulus in west Africa: a prospective study on surgical treatments. Dis Colon Rectum 1993; 36:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26453/abstract/39\">",
"      Cowlam S, Watson C, Elltringham M, et al. Percutaneous endoscopic colostomy of the left side of the colon. Gastrointest Endosc 2007; 65:1007.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2555 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-5AC2A9890B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26453=[""].join("\n");
var outline_f25_53_26453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2555\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2555|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/39/27254\" title=\"diagnostic image 1\">",
"      Sigmoid volvulus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8663?source=related_link\">",
"      Cecal volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=related_link\">",
"      Pathology and pathogenesis of Chagas disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_53_26454="Acropustulosis of infancy 1";
var content_f25_53_26454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77411%7EDERM%2F55499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77411%7EDERM%2F55499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acropustulosis of infancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small pustules are present on the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acropustulosis of infancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small pustules are present on the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26454=[""].join("\n");
var outline_f25_53_26454=null;
var title_f25_53_26455="Virology of human papillomavirus infections and the link to cancer";
var content_f25_53_26455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Virology of human papillomavirus infections and the link to cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26455/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26455/contributors\">",
"     Joel M Palefsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26455/contributors\">",
"     Ross D Cranston, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26455/contributors\">",
"     Bruce J Dezube, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26455/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/53/26455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) is the most commonly diagnosed sexually transmitted infection in the United States. It is associated with condyloma acuminata, anogenital (cervical, vaginal, vulval, penile, anal) squamous intraepithelial lesions and malignancy, and head and neck cancer.",
"   </p>",
"   <p>",
"    The biology of these viruses has been studied extensively because of this link with malignancies. The virology of HPV and its association with malignancy will be reviewed here. The clinical manifestations, diagnosis, epidemiology, prevention, and treatment of HPV infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV is a small deoxyribonucleic acid (DNA) virus of approximately 7900 base pairs. DNA sequencing techniques have facilitated HPV typing and characterization with each type formally defined as distinct by having less than 90 percent DNA base-pair homology with any another HPV type [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/1\">",
"     1",
"    </a>",
"    ]. There are over 40 HPV types that infect the anogenital area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV genotypes can be broadly split into &ldquo;high-risk&rdquo; (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and &ldquo;low-risk&rdquo; (6, 11, 40, 42, 43, 44, 53, 54, 61, 72, 73 and 81) based upon their phenotypic association with the development of cervical cancer. Types 16 and 18 are the most commonly isolated HPV types in cervical cancer with type 16 found in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/2\">",
"     2",
"    </a>",
"    ]. However, not all infections with HPV type 16 or 18 progress to cancer. Furthermore, within single oncogenic HPV types, variants exist that are associated with different oncogenic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/3\">",
"     3",
"    </a>",
"    ]. The epidemiology of these high-risk types is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link&amp;anchor=H746887#H746887\">",
"     \"Epidemiology of human papillomavirus infections\", section on 'Cervical cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HPV is also implicated in cancer of the anus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The spectrum of HPV types in the anal canal is similar to that described in the cervix and is associated with the same risk phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/4\">",
"     4",
"    </a>",
"    ]. HPV 16 is also the most commonly detected HPV type associated with anal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Using PCR typing techniques, one group has isolated 29 individual HPV types and 10 HPV groups from the anal canal of men who have sex with men (MSM), both with and without HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/4\">",
"     4",
"    </a>",
"    ]. The range of HPV types is similar in the HIV-positive and HIV-negative men. A few of the more commonly isolated HPV types in the anal samples have only rarely been reported in cervical samples (types 53, 58, 61, 70). HPV 32, characteristically an oral HPV type, was also isolated from anal samples and may indicate transmission by oral-anal intercourse.",
"   </p>",
"   <p>",
"    In a cohort of 346 HIV-infected and 262 HIV-negative men, multiple anal HPV types were more common in the HIV-infected patients (73 versus 23 percent). The presence of multiple high-risk HPV types was associated with significant immunosuppression (CD4 count below",
"    <span class=\"nowrap\">",
"     200/mm3)",
"    </span>",
"    in HIV-positive individuals. This finding could reflect increased reporting of receptive anal intercourse in this population or increased HPV replication in patients with the acquired immunodeficiency syndrome (AIDS). This is probably related to failure of local mucosal immunity and reactivation of HPV to reach detectable levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HPV infection is also a risk factor for carcinoma of the penis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one case-control study, 33 of 67 penile cancers were positive for HPV, of which 70 percent were HPV-16 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/8\">",
"     8",
"    </a>",
"    ]. Further, the risk of penile cancer among men reporting a history of condyloma acuminata was 5.9 times greater than that of men reporting no such history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=see_link\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, some oropharyngeal squamous cell cancers appear to be linked to HPV infection. There is an approximately two- to threefold increased risk for cancers of the oral cavity and oropharynx in patients infected with high-risk (oncogenic) HPV subtypes. Furthermore, the same high-risk sexual behaviors that increase the risk for anogenital HPV related cancers also increase the risk of oropharyngeal squamous cell cancers in HPV infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of HPV infections in the etiology of epithelial cancers has been supported by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HPV DNA is commonly present in anogenital and oral cancers and precancers",
"     </li>",
"     <li>",
"      Expression of the viral oncogenes E6 and E7 is consistently demonstrated in lesional tissue",
"     </li>",
"     <li>",
"      The E6 and E7 gene products have transforming properties by their interaction with growth-regulating host cell proteins",
"     </li>",
"     <li>",
"      In cervical carcinoma cell lines, continued E6 and E7 expression is necessary to maintain the malignant phenotype",
"     </li>",
"     <li>",
"      Epidemiologic studies indicate HPV infections as the major factor for the development of cervical cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HPV genome encodes DNA sequences for six early (E) proteins associated with viral gene regulation and cell transformation, two late (L) proteins which form the shell of the virus, and a region of regulatory DNA sequences known as the long control region or upstream regulatory region [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two most important HPV proteins in the pathogenesis of malignant disease are E6 and E7. Both E6 and E7 proteins are consistently expressed in HPV-carrying anogenital malignant tumors, and they act in a cooperative manner to immortalize epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/14\">",
"     14",
"    </a>",
"    ]. At the molecular level, the ability of E6 and E7 proteins to transform cells relates in part to their interaction with two intracellular proteins, p53 and retinoblastoma (Rb), respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=see_link\">",
"     \"Vaginal intraepithelial neoplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of p53 protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal cell, the p53 protein is a negative regulator of cell growth, controlling cell cycle transit from",
"    <span class=\"nowrap\">",
"     G0/G1",
"    </span>",
"    to S phase, and also functions as a tumor suppressor protein by halting cell growth after chromosomal damage and allowing DNA repair enzymes to function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Following E6 binding of p53, p53 is degraded in the presence of E6-associated protein [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/19\">",
"     19",
"    </a>",
"    ]. This allows unchecked cellular cycling, and has an anti-apoptotic effect, permitting the accumulation of chromosomal mutations without DNA repair [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This leads to chromosomal instability in high-risk HPV containing cells. The interaction of E6 with p53 may also affect regulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    degradation of the Src family of nonreceptor tyrosine kinases, potentially playing a role in the stimulation of mitotic activity in infected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/11,22\">",
"     11,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the E6 protein, E7 protein sensitizes wild-type p53-containing cells to apoptosis, but exerts an anti-apoptotic effect in cells with mutated p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The possible significance of this finding is discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of retinoblastoma protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rb protein inhibits the effect of positive growth regulation, and halts cell growth or induces cell apoptosis in response to DNA damage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. One of the functions of Rb is to bind and render inactive the E2F transcription factor. E2F controls DNA synthesis and cyclin function and promotes the S phase of cell cycling. E7 interacts with Rb protein via an",
"    <span class=\"nowrap\">",
"     E2F/Rb",
"    </span>",
"    protein complex. When E7 binds to Rb protein, E2F is released and allows cyclin A to promote cell cycling [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The interaction of E7 with Rb may permit cells with damaged DNA to bypass the G1 growth arrest normally induced by wild type p53 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/28\">",
"     28",
"    </a>",
"    ]. These processes allow unchecked cell growth in the presence of genomic instability that may lead to malignant change.",
"   </p>",
"   <p>",
"    In support of the importance of E7 in cellular transformation, inhibition of E7 binding to Rb abolishes its transforming ability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/29\">",
"     29",
"    </a>",
"    ]. However, other mechanisms of E7-mediated cell transformation probably also play a role. As an example, several interactions of E7 with transcription factors have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], and E7 proteins inactivate the cyclin-dependent kinase inhibitors p21(CIP-1) and p27(KIP-1), which may lead to growth stimulation of HPV infected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other HPV proteins that may be involved in malignant transformation of a cell are E1 (regulation of DNA replication and maintaining the virus in episomal form), E2 (cooperation with E1, viral DNA replication, regulation of E6 and E7 expression) and E5 (regulation of cell growth) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/12\">",
"     12",
"    </a>",
"    ]. The HPV genome exists in two forms. Most commonly, it is found in a circular episomal form that replicates autonomously outside the host cell chromosome but within the host cell nucleus. Under certain conditions associated with the development and presence of high-grade intraepithelial neoplasia and cancer, the episome linearizes and becomes integrated into the host cell genome. This change critically alters the E2 gene product and facilitates oncogenesis, since the site of linearization in the episomal form is usually within the E2 viral gene. This disrupts the repressor functions of E2, leading to increased expression of the E6 and E7 oncoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/26\">",
"     26",
"    </a>",
"    ]. In one study E2 produced growth arrest in HeLa cells by repression of the E6 and E7 promoter; expression of E6 and E7 off a different promoter reversed the growth arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the effects of immunosuppression, which promotes the persistence of HPV infection, coinfection with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/35\">",
"     35",
"    </a>",
"    ] may directly promote HPV associated oncogenesis at the molecular level. As an example, in vitro studies suggest that the HIV-encoded tat protein may enhance expression of the HPV E6 and E7 proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link&amp;anchor=H15#H15\">",
"     \"HIV and women\", section on 'Abnormal cervical cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Progression from immortalization to malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immortalization of human cells can be achieved with either HPV E6 or E7, but cooperative interaction between E6 and E7 enhances immortalization efficiency. However, neither the individual genes nor their cooperative interaction is sufficient to convert normal cells to the malignant phenotype. There are two hypotheses for how progression from immortalization to the malignant phenotype occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is some evidence that a separate signaling cascade within or between cells blocks the progression of immortalized cells to the malignant phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/37\">",
"       37",
"      </a>",
"      ]. Oncogene transcription or viral oncoprotein expression may be regulated in this manner via the retinoic acid receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/38\">",
"       38",
"      </a>",
"      ], or by cytokines such as transforming growth factor beta [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/39,40\">",
"       39,40",
"      </a>",
"      ], interferon-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/41\">",
"       41",
"      </a>",
"      ], or tumor necrosis factor (TNF)-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alterations in host cell DNA (eg, p53 mutations) may interact with viral oncoproteins by acting in concert with the oncogenes to permit progression from immortalization to transformation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/43\">",
"       43",
"      </a>",
"      ]. Alternatively, genetically unmodified high-risk HPV-infected human cells may be blocked from immortalization by intracellular control of viral oncoprotein function [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that intercellular cytokine-mediated control plays an important role in suppression of malignant transformation. Progression to the malignant phenotype probably involves a genetic change in the pathways controlling intracellular or intercellular signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/11\">",
"     11",
"    </a>",
"    ]. The chromosomal instability that characterizes HPV infection may be one mechanism leading to these genetic modifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR HPV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV is the most common sexually acquired infection in the United States. HPV has been detected in the epithelium of the penis, scrotum, anal canal, cervix, vulva, and perianal area. Genital HPV infections are considered to be spread by unprotected penetrative intercourse or close skin to skin physical contact involving an infected area [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/45\">",
"     45",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Digital/anal",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     digital/vaginal",
"    </span>",
"    contact probably can also spread the virus, as may fomites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DETECTING HPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of HPV is facilitated by recent advances in molecular biology. HPV testing is increasingly being used in clinical management of patients. HPV testing falls into three main categories [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26455/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HPV DNA testing &ndash; HPV DNA testing was the first approach developed for routine clinical testing. Many studies showed that the addition of HPV DNA testing to cervical cytology improved the sensitivity for detection of cervical cancer precursors, such as cervical intraepithelial neoplasia (CIN) 2 and 3. However, the specificity also decreased, resulting in the potential unnecessary referral of women for colposcopy.",
"     </li>",
"     <li>",
"      HPV RNA testing &ndash; HPV RNA testing, looking for expression of E6",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      E7 RNA, may be performed with the expectation that active HPV oncogene expression would provide better sensitivity and specificity than HPV DNA testing. Data thus far indicate that some of these tests do result in similar sensitivity to HPV DNA testing with slightly higher specificity. None of these tests are currently FDA-approved, although this is likely to change in the near future.",
"     </li>",
"     <li>",
"      Detection of cellular markers &ndash; Cellular marker detection uses a different approach to diagnosing HPV-associated disease. The HPV E7 protein disrupts cell cycling leading to an increase in cellular p16 protein expression. High-grade CIN lesions contain high levels of p16, and pathologists often immunostain cervical biopsies to help distinguish between high-grade CIN and immature squamous metaplasia, which is not associated with HPV and is not precancerous. Studies are in progress to determine the role of p16 staining to improve the sensitivity and specificity of cytology, similar to HPV DNA or RNA testing. None of the p16-based tests are FDA-approved at this time. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several HPV DNA tests that are currently approved by the FDA for clinical use. These include Hybrid Capture 2&trade; (HC2), Cervista&trade;, and the PCR-based Cobas 4800 test. HC2 detects a cocktail of 13 different high-risk (oncogenic) HPV types and reports the results as positive for one or more of these types, or negative for all. The Cervista and Cobas tests detect HPV 66 in addition to the 13 HPV types detected by HC2. The Cobas test identifies HPV types 16 and 18, while detecting the remaining 12 types in a probe mix. The Cervista test indicates positivity for one or more types in the 14-probe mix, but also offers the option of testing for HPV",
"    <span class=\"nowrap\">",
"     16/18",
"    </span>",
"    specifically. &nbsp;",
"   </p>",
"   <p>",
"    These tests can be used in similar fashion, and there are several possible indications for HPV DNA testing. Currently HPV testing can be used to determine whether women whose cervical cytology shows atypical squamous cells of undetermined significance (ASC-US) should be sent for colposcopy. Most often HPV testing in this setting is performed in a reflex fashion in conjunction with performance of liquid-based cytology. If the cytology shows ASC-US, then HPV testing is automatically performed on the leftover specimen.",
"   </p>",
"   <p>",
"    If the sample is positive for HPV, then the woman is referred for colposcopy and biopsy if a lesion is seen. If negative, the woman will be followed according to standard guidelines. HPV testing may also be used in conjunction with cervical cytology for primary screening of women over the age of 30 years. Women who are positive for either test are referred for colposcopy. Women who are negative for both are followed according to standard guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"       \"Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"       \"Patient information: Genital warts in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"       \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human papillomaviruses (HPVs) are small DNA viruses that are sexually transmitted and associated with squamous neoplasia of the anogenital region and oropharynx. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are multiple HPV phenotypes, which have differing risks for causing malignancy; HPV types 16 and 18 are highly prevalent in multiple types of cancer, including cervix, anus, and oropharynx. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Association with malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The E6 and E7 genes of HPV 16 and 18 appear to have a particularly important role in the development of malignancy, through the interactions of their respective protein products with the p53 tumor suppressor and the retinoblastoma protein. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Molecular pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/1\">",
"      Tilston P. Anal human papillomavirus and anal cancer. J Clin Pathol 1997; 50:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/2\">",
"      de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/3\">",
"      Hildesheim A, Schiffman M, Bromley C, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001; 93:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/4\">",
"      Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/5\">",
"      Bosch FX, Manos MM, Mu&ntilde;oz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/6\">",
"      Zaki SR, Judd R, Coffield LM, et al. Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol 1992; 140:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/7\">",
"      Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997; 337:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/8\">",
"      Maden C, Sherman KJ, Beckmann AM, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993; 85:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/9\">",
"      Varma VA, Sanchez-Lanier M, Unger ER, et al. Association of human papillomavirus with penile carcinoma: a study using polymerase chain reaction and in situ hybridization. Hum Pathol 1991; 22:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/10\">",
"      D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/11\">",
"      zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/12\">",
"      Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/13\">",
"      Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 1994; 8:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/14\">",
"      M&uuml;nger K, Phelps WC, Bubb V, et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63:4417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/15\">",
"      Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989; 244:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/16\">",
"      Masuda H, Miller C, Koeffler HP, et al. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A 1987; 84:7716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/17\">",
"      Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/18\">",
"      Dupuy C, Buzoni-Gatel D, Touze A, et al. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 1997; 22:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/19\">",
"      Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/20\">",
"      Havre PA, Yuan J, Hedrick L, et al. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995; 55:4420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/21\">",
"      Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/22\">",
"      Oda H, Kumar S, Howley PM. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc Natl Acad Sci U S A 1999; 96:9557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/23\">",
"      Puthenveettil JA, Frederickson SM, Reznikoff CA. Apoptosis in human papillomavirus16 E7-, but not E6-immortalized human uroepithelial cells. Oncogene 1996; 13:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/24\">",
"      Magal SS, Jackman A, Pei XF, et al. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. Int J Cancer 1998; 75:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/25\">",
"      Pagano M, D&uuml;rst M, Joswig S, et al. Binding of the human E2F transcription factor to the retinoblastoma protein but not to cyclin A is abolished in HPV-16-immortalized cells. Oncogene 1992; 7:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/26\">",
"      Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/27\">",
"      Tommasino M, Adamczewski JP, Carlotti F, et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/28\">",
"      Demers GW, Foster SA, Halbert CL, Galloway DA. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A 1994; 91:4382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/29\">",
"      Brehm A, Nielsen SJ, Miska EA, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999; 18:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/30\">",
"      Antinore MJ, Birrer MJ, Patel D, et al. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J 1996; 15:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/31\">",
"      Massimi P, Pim D, Banks L. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J Gen Virol 1997; 78 ( Pt 10):2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/32\">",
"      Jones DL, Alani RM, M&uuml;nger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997; 11:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/33\">",
"      Zerfass-Thome K, Zwerschke W, Mannhardt B, et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996; 13:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/34\">",
"      Francis DA, Schmid SI, Howley PM. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 2000; 74:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/35\">",
"      Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/36\">",
"      Vernon SD, Hart CE, Reeves WC, Icenogle JP. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 1993; 27:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/37\">",
"      Chen Z, Kamath P, Zhang S, et al. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther 1995; 2:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/38\">",
"      Bartsch D, Boye B, Baust C, et al. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 1992; 11:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/39\">",
"      Braun L, D&uuml;rst M, Mikumo R, Gruppuso P. Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor beta 1. Cancer Res 1990; 50:7324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/40\">",
"      Woodworth CD, Notario V, DiPaolo JA. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 1990; 64:4767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/41\">",
"      Khan MA, Tolleson WH, Gangemi JD, Pirisi L. Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons. J Virol 1993; 67:3396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/42\">",
"      Soto U, Das BC, Lengert M, et al. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene 1999; 18:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/43\">",
"      Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/44\">",
"      Chen TM, Pecoraro G, Defendi V. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. Cancer Res 1993; 53:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/45\">",
"      Palefsky JM. Cutaneous and genital HPV-associated lesions in HIV-infected patients. Clin Dermatol 1997; 15:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26455/abstract/46\">",
"      Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011; 103:368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8031 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-75F91836D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26455=[""].join("\n");
var outline_f25_53_26455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSOCIATION WITH MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of p53 protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of retinoblastoma protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Progression from immortalization to malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS FOR HPV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DETECTING HPV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=related_link\">",
"      Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=related_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=related_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=related_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5560?source=related_link\">",
"      Vaginal intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_53_26456="Nutritional antioxidants in coronary heart disease";
var content_f25_53_26456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutritional antioxidants in coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26456/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26456/contributors\">",
"     Christine C Tangney, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26456/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26456/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26456/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/53/26456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antioxidants have been evaluated for both primary and secondary prevention of coronary heart disease (CHD). Studies of the mechanisms of atherosclerosis suggest that antioxidants might be protective. Observational studies appeared to show benefits with higher intake of some antioxidants. Additionally, cardiovascular protection has been associated with dietary patterns high in antioxidants (from fruit and vegetables) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/1\">",
"     1",
"    </a>",
"    ], and with higher circulating levels of alpha tocopherol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/2\">",
"     2",
"    </a>",
"    ]. However, most randomized, controlled trials have not found antioxidant supplementation to be effective for the prevention of CHD.",
"   </p>",
"   <p>",
"    The potential efficacy of the nutritional antioxidants vitamin E, vitamin C, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    and other carotenoids is reviewed here. Each is considered separately, as each appears to have distinct risks and benefits.",
"   </p>",
"   <p>",
"    It is more difficult to assess the efficacy of dietary antioxidants in randomized trials. The association between dietary antioxidants and cardioprotection, despite the lack of benefits seen in trials of supplements, may reflect issues of confounding and bias in observational studies, or may occur because the full complement of antioxidants in foods are different from what is found in supplements or are present in more optimal ratios.",
"   </p>",
"   <p>",
"    The role of antioxidants in conditions other than CHD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H18#H18\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Antioxidant vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also discussed separately are the effects of the antioxidant probucol on lipids, and the effects of probucol and succinobucol on cardiovascular outcomes after percutaneous coronary intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H10#H10\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Probucol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/25/29081?source=see_link\">",
"     \"Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation and oxidative stress are critical to the initiation and progression of atherosclerosis. Oxidation of proteins and lipid peroxidation of membrane polyunsaturated fatty acids in lipoproteins by reactive oxygen species can facilitate the development of atherosclerotic lesions (",
"    <a class=\"graphic graphic_figure graphicRef72955 \" href=\"UTD.htm?32/53/33629\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Absolute levels of modified LDL are proportional to those of total LDL. Thus, oxidatively modified LDL species are likely to be greater in hypercholesterolemic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] and among those with metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is, however, considerable interindividual variability in oxyradical generation. This variability may be dependent in part upon the distribution of LDL subspecies, since small dense LDLs are more susceptible to oxidative modification than large buoyant LDL subspecies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/10\">",
"     10",
"    </a>",
"    ]. The small dense LDL profile often coexists with elevated triglycerides and both attributes appear to confer cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Data from the Physicians Health Study, for example, demonstrated that elevated nonfasting triglycerides and a predominance of small dense LDL particles were highly predictive of future myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/11\">",
"     11",
"    </a>",
"    ]. Furthermore, men with dense LDL profiles appear to benefit most from risk reduction interventions as assessed by angiographic changes over four years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another factor that may influence the variability of oxidative stress from one individual to another is the inactivation of reactive oxygen species by endogenous enzymes. In one study, the activity of glutathione oxidase 1, a key intracellular antioxidant enzyme, was measured in red blood cells in 636 patients with suspected coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/14\">",
"     14",
"    </a>",
"    ]. At five years, the incidence of cardiovascular events was inversely associated with increasing quartiles of glutathione oxidase 1 activity.",
"   </p>",
"   <p>",
"    Ingestion of antioxidants may prevent or retard atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/3\">",
"     3",
"    </a>",
"    ]. Such a benefit might be mediated by several mechanisms (",
"    <a class=\"graphic graphic_figure graphicRef64231 \" href=\"UTD.htm?16/47/17142\">",
"     figure 2",
"    </a>",
"    ). With respect to vitamin C and alpha tocopherol (vitamin E), for example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin C is a potent endogenous antioxidant that regulates intracellular redox state through its interaction with glutathione and is capable of scavenging oxygen-derived free radicals (",
"      <a class=\"graphic graphic_figure graphicRef53280 \" href=\"UTD.htm?41/8/42125\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin C reverses defects induced by smoking, including oxidant stress [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/18,19\">",
"       18,19",
"      </a>",
"      ] and increased monocyte adhesion to endothelium [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin C might influence coronary artery disease through an effect on lesion activity rather than a reduction in the overall extent of fixed lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The enhanced oxidative susceptibility of small dense LDL appears to be related to reduced content of alpha tocopherol or a reduced alpha tocopherol-to-polyunsaturated fatty acid (PUFA) ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/10,22,23\">",
"       10,22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study of patients with carotid artery stenosis who received radiolabeled native LDL prior to endarterectomy found that circulating LDL rapidly accumulated in the foam cells, but not the lipid core, of atherosclerotic plaque [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/24\">",
"       24",
"      </a>",
"      ]. This was almost completely prevented by four weeks of vitamin E therapy.",
"      <br/>",
"      <br/>",
"      In male cigarette smokers, alpha tocopherol supplements attenuate the transient increase in endothelial dysfunction that occurs after heavy cigarette smoking but do not reverse chronic underlying dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"       \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Alpha tocopherol also reverses endothelial dysfunction in patients with variant angina. As an example, treatment for one month with 300 mg per day of alpha tocopherol in 60 patients with vasospastic angina improved flow-dependent vasodilation in peripheral arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/26\">",
"       26",
"      </a>",
"      ]. This improvement was associated with a reduction in anginal attacks and evidence of peroxidation, as measured by plasma levels of thiobarbituric acid reactive substances [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"       \"Variant angina\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin E supplementation (400 IU daily) increases arterial compliance after four and eight weeks of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alpha tocopherol inhibits platelet aggregation and prevents intraarterial thrombus formation at levels attainable by supplementation; this effect is mediated by its incorporation into the platelet and inhibition of platelet protein kinase C stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/28\">",
"       28",
"      </a>",
"      ]. Alpha tocopherol also inhibits platelet adhesion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/29\">",
"       29",
"      </a>",
"      ]. It has been suggested that a low dose (75",
"      <span class=\"nowrap\">",
"       IU/day)",
"      </span>",
"      is optimal for platelet uptake; this dose is also associated with maximal inhibition of platelet aggregation by prostaglandin E1 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/30\">",
"       30",
"      </a>",
"      ]. In an animal model, gamma tocopherol also decreased platelet aggregation and the tendency to thrombus formation; it has a more potent effect than alpha tocopherol [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alpha tocopherol supplementation decreases monocyte-endothelial cell adhesion by decreasing the expression of &szlig;-1 and &szlig;-2 integrin adhesion molecules on the surface of the monocyte [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/32\">",
"       32",
"      </a>",
"      ] and by reducing the expression of inflammatory cell adhesion markers [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alpha tocopherol has inhibitory effects on smooth muscle proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION OF CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of vitamin C, vitamin E, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    have been evaluated in the primary prevention of CHD. Although observational studies of dietary vitamin E have been encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/35\">",
"     35",
"    </a>",
"    ], observational studies with vitamin C have had conflicting results. Based on randomized trials, supplementation with vitamin E, vitamin C, and beta-carotene have not been shown to be useful for primary prevention whether given alone or in combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies, including studies of 88,000 women in the Nurses' Health Study and almost 40,000 male health professionals, found that supplementation with at least 100 IU of vitamin E per day was associated with a lower risk of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. A third observational study of 34,000 postmenopausal women also reported that dietary intake of vitamin E was inversely related to the risk of death from CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/38\">",
"     38",
"    </a>",
"    ]. However, randomized trials have not found a benefit of supplementation with vitamin E for primary prevention of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Finnish Alpha Tocopherol",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      Cancer Prevention Study followed 27,271 male smokers for a median of six years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/39\">",
"       39",
"      </a>",
"      ]. Daily supplementation with 50 mg (75 IU) of vitamin E had no significant effect on the incidence of myocardial infarction and cardiac death [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/39\">",
"       39",
"      </a>",
"      ], although a separate analysis found a slight decrease in the risk of developing angina [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial in 4495 subjects with one or more risk factors for CHD (hypertension, hypercholesterolemia, diabetes, obesity, family history of premature myocardial infarction, or elderly individuals) found that daily supplementation with 300 mg (450 IU) of vitamin E had no effect on the primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Women's Health Study followed 39,876 apparently healthy women ages 45 and older for a mean of 10.1 years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/42\">",
"       42",
"      </a>",
"      ]. Compared with placebo, supplementation with 600 IU of natural-source vitamin E on alternate days had no significant effect on the primary endpoint of a first major cardiovascular event (relative risk 0.93, 95% CI 0.82-1.05) or on all-cause mortality (RR 1.04, CI 0.93-1.16). Additional subgroup analyses found no effect on the incidence of myocardial infarction or stroke but did show a reduction in cardiovascular mortality (RR 0.76, CI 0.59-0.98). Given the lack of benefit seen in the primary endpoint and in all-cause mortality, the authors concluded that the study did not support supplementation with vitamin E to prevent CHD in healthy women.",
"     </li>",
"     <li>",
"      The Physicians' Health Study II randomly assigned 14,641 physicians to treatment with vitamin E 400 IU daily, vitamin C 500 mg daily, both, or neither; 95 percent of subjects had no CHD at the time of randomization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/43\">",
"       43",
"      </a>",
"      ]. After a mean follow-up of 8 years, treatment with vitamin E had no effect on the primary composite endpoint of major cardiovascular events (hazard ratio [HR] 1.01, 95% CI 0.90-1.13). There was no statistically significant effect on all-cause mortality (HR 1.07, CI 0.97-1.18).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This lack of effect in randomized trials is consistent with the lack of benefit seen with the use of vitamin E for secondary prevention. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Secondary prevention of CHD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additionally, high-dose vitamin E supplementation (&ge;400",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    may be associated with an increase in all-cause mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H26#H26\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Vitamin E'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Beta-carotene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized, double-blind, placebo-controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    for primary prevention of CHD have found no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/39,44-46\">",
"     39,44-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      and Retinol Efficacy Trial evaluated the combined treatment of beta-carotene (30",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus retinol (vitamin A, 25,000",
"      <span class=\"nowrap\">",
"       IU/day)",
"      </span>",
"      in 18,000 men and women at high risk for lung cancer (smokers, former smokers, asbestos exposed) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/44\">",
"       44",
"      </a>",
"      ]. After a mean treatment time of four years, the relative risk of death from cardiovascular disease in the treated group was 1.26 (95% CI 0.99-1.61).",
"     </li>",
"     <li>",
"      The Physicians' Health Study evaluated 22,071 men randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      supplementation (50 mg on alternate days) or placebo for 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/45\">",
"       45",
"      </a>",
"      ]. There was no difference in the incidence of cardiovascular disease (death or myocardial infarction) between the two groups.",
"     </li>",
"     <li>",
"      The Women's Health Study evaluated 39,876 women over the age of 45 who were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      supplements (50 mg on alternate days) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/46\">",
"       46",
"      </a>",
"      ]. Supplementation had no impact on cardiovascular disease (death or myocardial infarction).",
"     </li>",
"     <li>",
"      The Finnish Alpha Tocopherol",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      Cancer Prevention Study followed 27,271 male smokers for a median of six years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/39\">",
"       39",
"      </a>",
"      ]. Daily treatment with beta-carotene (20 mg) had no effect on cardiovascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vitamin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies of vitamin C in primary prevention of CHD have had conflicting results with some suggesting a beneficial effect associated with vitamin C [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/47-50\">",
"     47-50",
"    </a>",
"    ], while others found so such benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/36,37,51\">",
"     36,37,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only large randomized trial to address this issue, the Physicians' Health Study II, randomly assigned 14,641 physicians to treatment with vitamin C 500 mg daily, vitamin E 400 IU daily, both, or neither; 95 percent of subjects had no CHD at the time of randomization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/43\">",
"     43",
"    </a>",
"    ]. After a mean follow-up of 8 years, treatment with vitamin C had no effect on the primary composite endpoint of major cardiovascular events (hazard ratio [HR] 0.99, 95% CI 0.89-1.11). There was no statistically significant effect on all-cause mortality (HR 1.07, CI 0.97-1.18).",
"   </p>",
"   <p>",
"    This lack of effect in a randomized trial is consistent with the lack of benefit seen with the use of vitamin C for secondary prevention. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Secondary prevention of CHD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Multivitamin supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared a daily supplement containing antioxidants (vitamin C 120 mg, vitamin E 45 IU,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    6 mg) and minerals (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    100 mcg, zing 20 mg) with placebo in 13,017 adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/52\">",
"     52",
"    </a>",
"    ]. After a median follow-up of 7.5 years, there was no significant effect on the risk of cardiovascular disease (relative risk 0.97). However, a reduction in all-cause mortality was seen in men taking the supplement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H48#H48\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Multivitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION OF CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large clinical trials have studied the effect of supplementation with vitamin C, vitamin E, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    on secondary prevention of CHD. For most patients, there is no convincing evidence of benefit alone or in combination, and beta-carotene may be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. One study suggested that vitamin E supplementation may have benefit in patients on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Finnish Alpha Tocopherol",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      Cancer Prevention Study has issued a series of reports that assessed the role of antioxidant vitamins in patients with CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/53,56,57\">",
"       53,56,57",
"      </a>",
"      ]. In one, 1862 male smokers who had a previous myocardial infarction were randomly assigned to treatment with alpha tocopherol (50 mg per day), beta-carotene (20 mg per day), both, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/53\">",
"       53",
"      </a>",
"      ]. The endpoint was the first major coronary event. After five years of follow-up, there were significantly more cardiac deaths in the group taking both supplements (relative risk 1.58) and those taking beta-carotene (relative risk 1.75) (",
"      <a class=\"graphic graphic_figure graphicRef77207 \" href=\"UTD.htm?35/42/36526\">",
"       figure 4",
"      </a>",
"      ). Alpha tocopherol alone did not significantly increase the risk of cardiac death. Similar findings were noted in an analysis of the subgroup of men with preexisting CHD in the Physician's Health Study: beta-carotene supplementation was associated with a nonsignificant increase in cardiovascular deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/54\">",
"       54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Another ATBC report evaluated 1795 male smokers with angina [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/57\">",
"       57",
"      </a>",
"      ]. Neither alpha tocopherol nor beta-carotene had any effect on the progression from mild to severe angina or on the risk of a major coronary event (fatal or non-fatal myocardial infarction).",
"     </li>",
"     <li>",
"      The Heart Outcome Prevention Evaluation (HOPE) trial evaluated vitamin E (400",
"      <span class=\"nowrap\">",
"       IU/day)",
"      </span>",
"      in 9541 patients over the age of 55 years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/58\">",
"       58",
"      </a>",
"      ]. The patients had either evidence of vascular disease or were at high risk because they had diabetes and at least one coronary risk factor. After a mean follow-up of 4.5 years, there was no effect of vitamin E on the primary endpoint (cardiovascular death, myocardial infarction, or stroke) or any of its individual components or any of the secondary endpoints. A 2.5 year extension of the trial (HOPE-TOO) also found no effect of vitamin E on the primary combined cardiovascular endpoint after a median follow-up of 7.2 years, however patients appeared to have an increased risk of heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Heart failure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The Heart Protection Study randomized 20,536 patients who had a history of CHD, vascular disease, or diabetes mellitus to five years of antioxidant vitamin supplementation (vitamin E 600 mg [900 IU], vitamin C 250 mg, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      20 mg) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/60\">",
"       60",
"      </a>",
"      ]. Supplementation had no effect on cardiovascular mortality and nonfatal myocardial infarction.",
"     </li>",
"     <li>",
"      The Women's Antioxidant Cardiovascular Study evaluated vitamin C (500",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      vitamin E (600 IU every other day), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      (50 mg every other day) alone or in combination (2 x 2 x 2 factorial design) in 8171 female health professionals ages 40 and older with CVD or three or more CVD risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/61\">",
"       61",
"      </a>",
"      ]. After a mean follow-up of 9.4 years, antioxidant therapy had no overall effects on cardiovascular events.",
"     </li>",
"     <li>",
"      The Women's Angiographic Vitamin and Estrogen (WAVE) randomly assigned 423 postmenopausal women with CHD to twice daily treatment with vitamin C (500 mg) plus vitamin E (400 IU) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/62\">",
"       62",
"      </a>",
"      ]. More women receiving vitamin supplementation died (16 versus 6, hazard ratio 2.8, 95% CI 1.1-7.2). A separate comparison in the study also suggested harm from hormone replacement therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The GISSI prevention trial randomly assigned 11,324 patients within three months of a myocardial infarction to daily supplementation with vitamin E 300 mg (450 IU) or placebo. Vitamin E, administered alone or in combination with fish oil, had no effect on outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Cambridge Heart Antioxidant Study (CHAOS) evaluated relatively large doses of vitamin E supplementation (400 IU or 800 IU, 13 to 26 times the Daily Value [DV, previously RDA]) versus placebo in 2002 men and women with angiographic evidence of CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/64\">",
"       64",
"      </a>",
"      ]. Vitamin E reduced the one-year rate of nonfatal myocardial infarction, but did not improve cardiovascular mortality.",
"     </li>",
"     <li>",
"      The SPACE trial randomly assigned 196 patients with chronic renal failure on hemodialysis to vitamin E (800 IU per day) or placebo for a median of 520 days. There was a significant reduction in the primary endpoint (fatal or nonfatal myocardial infarction, ischemic stroke, peripheral vascular disease, and unstable angina) with vitamin E (16 versus 33 percent, relative risk 0.46) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the overwhelming majority of evidence suggests that there is no benefit from antioxidants for secondary prevention of CHD. One exception may be the use of vitamin E in patients receiving hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who remained enrolled in the 2.5 year extension of the HOPE trial (HOPE-TOO) described above (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Secondary prevention of CHD'",
"    </a>",
"    above), patients treated with vitamin E had a significantly increased risk of heart failure (relative risk [RR] 1.19, 95% CI 1.05-1.35) and of hospitalization for heart failure (RR 1.40, CI 1.13-1.73) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although concerning, this was a result from a subset analysis and has not been reported in other trials of vitamin E. The authors of the HOPE-TOO trial recommended that a meta-analysis of completed trials be performed to further address this concern [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supplementation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      , vitamin E, and vitamin C, either alone or in combination with each other or other antioxidant vitamins does",
"      <strong>",
"       not",
"      </strong>",
"      appear to be efficacious for the primary or secondary prevention of CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/65\">",
"       65",
"      </a>",
"      ]. Additionally, high-dose vitamin E supplementation (&ge;400",
"      <span class=\"nowrap\">",
"       IU/day)",
"      </span>",
"      may be associated with an increase in all-cause mortality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H26#H26\">",
"       \"Vitamin supplementation in disease prevention\", section on 'Vitamin E'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-carotene",
"      </a>",
"      supplementation may be dangerous and should be discouraged.",
"     </li>",
"     <li>",
"      Vitamin E supplementation may be of benefit for secondary prevention of CHD in patients with chronic renal failure who are undergoing hemodialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are consistent with those of the third United States Preventive Services Task Force (USPSTF), which found insufficient evidence to recommend for or against supplements of vitamins A, C, E, or antioxidant combinations for the prevention of cardiovascular disease, and recommended against the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    supplements for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/66\">",
"     66",
"    </a>",
"    ]. The USPSTF clinical practice guideline for routine vitamin supplementation to prevent cancer and cardiovascular disease, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    . Similarly, the American Heart Association concluded that current data do not justify the use of antioxidant supplements for the prevention or treatment of cardiovascular disease risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26456/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above recommendations apply to supplementation only. Diets high in antioxidants are associated with lower cardiovascular mortality, although whether this is due to their antioxidant content is unknown. Recommendations for supplementation with vitamin C, vitamin E, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    for conditions other than CHD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H18#H18\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Antioxidant vitamins'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/1\">",
"      Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr 2006; 136:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/2\">",
"      Wright ME, Lawson KA, Weinstein SJ, et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 2006; 84:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/3\">",
"      Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/4\">",
"      Savenkova ML, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994; 269:20394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/5\">",
"      Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/6\">",
"      Sevanian A, Hwang J, Hodis H, et al. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996; 16:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/7\">",
"      Hodis HN, Kramsch DM, Avogaro P, et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J Lipid Res 1994; 35:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/8\">",
"      Cazzolato G, Avogaro P, Bittolo-Bon G. Characterization of a more electronegatively charged LDL subfraction by ion exchange HPLC. Free Radic Biol Med 1991; 11:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/9\">",
"      Holvoet P, Lee DH, Steffes M, et al. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 2008; 299:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/10\">",
"      Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/11\">",
"      Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/12\">",
"      Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/13\">",
"      Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996; 94:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/14\">",
"      Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/15\">",
"      Meister A. Glutathione-ascorbic acid antioxidant system in animals. J Biol Chem 1994; 269:9397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/16\">",
"      Block G, Henson DE, Levine M. Vitamin C: a new look. Ann Intern Med 1991; 114:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/17\">",
"      Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Anti- rather than prooxidant activity of vitamin C in the presence of transition metal ions. J Biol Chem 1993; 268:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/18\">",
"      Harats D, Ben-Naim M, Dabach Y, et al. Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking. Atherosclerosis 1990; 85:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/19\">",
"      Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/20\">",
"      Weber C, Erl W, Weber K, Weber PC. Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation 1996; 93:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/21\">",
"      Vita JA, Keaney JF Jr, Raby KE, et al. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol 1998; 31:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/22\">",
"      Tribble DL, Thiel PM, van den Berg JJ, Krauss RM. Differing alpha-tocopherol oxidative lability and ascorbic acid sparing effects in buoyant and dense LDL. Arterioscler Thromb Vasc Biol 1995; 15:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/23\">",
"      Tribble DL, van den Berg JJ, Motchnik PA, et al. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci U S A 1994; 91:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/24\">",
"      Iuliano L, Mauriello A, Sbarigia E, et al. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque : effect of vitamin E supplementation. Circulation 2000; 101:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/25\">",
"      Neunteufl T, Priglinger U, Heher S, et al. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J Am Coll Cardiol 2000; 35:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/26\">",
"      Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol 1998; 32:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/27\">",
"      Mottram P, Shige H, Nestel P. Vitamin E improves arterial compliance in middle-aged men and women. Atherosclerosis 1999; 145:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/28\">",
"      Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr. alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996; 94:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/29\">",
"      Steiner M. Vitamin E: more than an antioxidant. Clin Cardiol 1993; 16:I16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/30\">",
"      Mabile L, Bruckdorfer KR, Rice-Evans C. Moderate supplementation with natural alpha-tocopherol decreases platelet aggregation and low-density lipoprotein oxidation. Atherosclerosis 1999; 147:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/31\">",
"      Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 1999; 34:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/32\">",
"      Islam KN, Devaraj S, Jialal I. alpha-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells. Circulation 1998; 98:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/33\">",
"      Wu D, Koga T, Martin KR, Meydani M. Effect of vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis 1999; 147:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/34\">",
"      Boscoboinik D, Szewczyk A, Hensey C, Azzi A. Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C. J Biol Chem 1991; 266:6188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/35\">",
"      Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009; 169:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/36\">",
"      Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/37\">",
"      Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/38\">",
"      Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/39\">",
"      Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998; 158:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/40\">",
"      de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/41\">",
"      Rapola JM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA 1996; 275:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/42\">",
"      Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/43\">",
"      Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008; 300:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/44\">",
"      Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/45\">",
"      Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/46\">",
"      Lee IM, Cook NR, Manson JE, et al. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/47\">",
"      Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/48\">",
"      Khaw KT, Bingham S, Welch A, et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 2001; 357:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/49\">",
"      Nyyss&ouml;nen K, Parviainen MT, Salonen R, et al. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997; 314:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/50\">",
"      Osganian SK, Stampfer MJ, Rimm E, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol 2003; 42:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/51\">",
"      Gale CR, Martyn CN, Winter PD, Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ 1995; 310:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/52\">",
"      Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/53\">",
"      Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/54\">",
"      Gaziano JM, Manson JE, Ridker PM, et al. Beta carotene therapy for chronic stable angina. Circulation 1996; 94(Suppl I):508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/55\">",
"      Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/56\">",
"      The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/57\">",
"      Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart 1998; 79:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/58\">",
"      Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/59\">",
"      Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/60\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/61\">",
"      Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007; 167:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/62\">",
"      Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/63\">",
"      Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/64\">",
"      Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/65\">",
"      Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/66\">",
"      U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale. Ann Intern Med 2003; 139:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26456/abstract/67\">",
"      Kris-Etherton PM, Lichtenstein AH, Howard BV, et al. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004; 110:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6836 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26456=[""].join("\n");
var outline_f25_53_26456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY PREVENTION OF CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Beta-carotene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vitamin C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Multivitamin supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SECONDARY PREVENTION OF CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6836|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/53/33629\" title=\"figure 1\">",
"      Oxidized LDL endothelial injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/47/17142\" title=\"figure 2\">",
"      Antioxidants and atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/8/42125\" title=\"figure 3\">",
"      Vitamin C and CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36526\" title=\"figure 4\">",
"      Antioxidants and mortality MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/25/29081?source=related_link\">",
"      Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_53_26457="SLE Proliferative";
var content_f25_53_26457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing membranoproliferative lupus nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing a membranoproliferative pattern in lupus nephritis, characterized by areas of cellular proliferation (long arrows) and by thickening of the glomerular capillary wall (due to immune deposits) that may be prominent enough to form a \"wire-loop\" (short arrows). Although proliferative changes can be focal (affecting less than 50 percent of glomeruli), disease of this severity is usually diffuse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26457=[""].join("\n");
var outline_f25_53_26457=null;
var title_f25_53_26458="Treatment of leptomeningeal metastases (carcinomatous meningitis)";
var content_f25_53_26458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26458/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26458/contributors\">",
"     Alexis Demopoulos, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26458/contributors\">",
"     Paul Brown, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26458/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/53/26458/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26458/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/53/26458/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/53/26458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer arising outside the central nervous system (CNS) can metastasize to any intracranial structure, including the membranes covering the brain. These membranes consist of the dura mater, and the arachnoid and pia mater, the latter two together are called the leptomeninges. The subarachnoid space lies between the arachnoid and pia mater and contains the cerebrospinal fluid (CSF) and arteries supplying the brain parenchyma. When tumor invades the leptomeninges, tumor cells can be disseminated via the CSF and spread throughout the subarachnoid space, causing multifocal signs and symptoms.",
"   </p>",
"   <p>",
"    The treatment of leptomeningeal metastases from solid tumors is reviewed here. The pathophysiology, clinical manifestations, and diagnosis of leptomeningeal metastases, and leptomeningeal involvement in hematologic malignancies, especially large cell lymphomas and acute leukemias, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Leptomeningeal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment include stabilizing or improving neurologic function, prolonging survival and if these are not possible, palliating symptoms. However, the prognosis varies considerably, depending upon the tumor type and extent of both neurologic and systemic disease; these factors can help determine the appropriate therapeutic approach for an individual patient. The key parameters separating poor-risk from good-risk patients are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef54352 \" href=\"UTD.htm?6/44/6859\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Poor-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a low Karnofsky performance status (KPS) (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ), multiple, serious, fixed neurologic deficits, and extensive systemic cancer with limited therapeutic options have a poor prognosis even with active treatment. Management of leptomeningeal metastases in this setting focuses on alleviating symptoms. A palliative approach should also be considered for patients with leptomeningeal gliomatosis and those with encephalopathy due to extensive brain infiltration (carcinomatous encephalitis), since the prognosis is poor even with combined modality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The palliative regimen can include the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy (RT) can be useful for relief of symptoms caused by localized leptomeningeal metastases.",
"     </li>",
"     <li>",
"      Analgesics are given for persistent pain.",
"     </li>",
"     <li>",
"      Corticosteroids rarely reverse neurologic deficits from leptomeningeal metastases (except sometimes when the disease is breast cancer, leukemia, or lymphoma), but they may improve headache and radicular pain more effectively than analgesics.",
"     </li>",
"     <li>",
"      Anticonvulsants should be reserved for patients with seizures (10 to 20 percent of cases) and routine prophylactic use should be avoided. CNS metastases from melanoma (either brain or leptomeningeal) may be an exception. These tumors are associated with a high incidence of seizures, probably a result of their tendency to involve the cortex and hemorrhage. Prophylactic anticonvulsants may decrease the incidence [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link&amp;anchor=H784669897#H784669897\">",
"       \"Seizures in patients with primary and metastatic brain tumors\", section on 'Patients without a history of a seizure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serotonin reuptake inhibitors or stimulant medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      ) may be beneficial for patients with significant depression or fatigue. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"       \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Good-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good-risk patients include those with a KPS of 60 or above, modest or no fixed neurologic deficits, minimal systemic disease burden,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a cancer for which there are reasonable treatment options. For these individuals, treatment is directed at controlling the tumor. RT is used to treat bulky or symptomatic areas of leptomeningeal disease, intrathecal (IT) or systemic chemotherapy that can cross the blood brain barrier is given to achieve therapeutic concentrations in the CSF, and extraneural tumor is treated aggressively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of leptomeningeal metastases in good-risk patients must be directed toward the entire neuraxis. If therapy is limited to symptomatic areas, disease progression inevitably occurs in untreated sites. An exception to this principle is irradiation of the entire neuroaxis is typically not performed due to the potential toxicity of craniospinal RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Increased ICP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated ICP is treated initially with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and a dose of 8 mg twice a day is usually effective. Dexamethasone should be started early and the dose reduced as quickly as possible until the lowest effective dose is achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If elevated ICP cannot be controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , a ventriculoperitoneal (VP) shunt can relieve hydrocephalus and other symptoms of elevated intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/4\">",
"     4",
"    </a>",
"    ]. In experienced hands, VP shunting is safe and efficacious. A report of VP shunting in 37 consecutive patients with hydrocephalus caused by leptomeningeal metastases reported substantial relief of symptoms in most patients and complications that were related only to shunt placement (one cerebral hemorrhage probably caused by poor technique) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/5\">",
"     5",
"    </a>",
"    ]. No patient suffered infection or abdominal seeding, perhaps because postoperative survival was relatively short.",
"   </p>",
"   <p>",
"    One caveat is that \"communicating hydrocephalus\" caused by leptomeningeal metastases may substantially elevate intracranial pressure and cause symptoms without significantly increasing size of the ventricles. A VP shunt is not needed in this circumstance. The diagnosis can be made by measuring pressure at lumbar puncture.",
"   </p>",
"   <p>",
"    For patients with elevated ICP and obstructive hydrocephalus, shunting is",
"    <strong>",
"     avoided",
"    </strong>",
"    unless absolutely necessary. In addition to perioperative morbidity and mortality, potential complications arising after shunt placement include infection, failure due to tumor deposition within the shunt, and tumor seeding of the abdominal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, intrathecal therapy is no longer possible as the injected material is immediately shunted into the abdominal cavity. An off-on valve is ineffective as the injected agent remains in the ventricular system and diffuses into the surrounding brain increasing potential toxicity, until the valve is opened.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pretreatment CSF flow study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to RT or IT chemotherapy, a CSF flow study via a radionuclide cisternogram is desirable although not available in all centers. This study will identify areas of obstruction that will prevent the chemotherapy from being homogeneously distributed, potentially decreasing efficacy and increasing toxicity. As an example, the administration of intraventricular MTX through an Ommaya reservoir can cause leukoencephalopathy even at conventional doses if there is a block to egress of the drug from the ventricular system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H7#H7\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Leukoencephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal CSF flow is seen in up to two-thirds of patients with leptomeningeal metastases, often without evidence of hydrocephalus or other abnormalities on conventional neuroimaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Common sites of obstructed CSF flow include the base of the brain (ventricular outlet obstruction), within the spinal canal, and over the cortical convexities.",
"   </p>",
"   <p>",
"    RT to areas of obstruction, even if no lesion is identified by MRI, can reverse the flow abnormality, thereby improving the effectiveness of IT chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meticulous assessment of the response to therapy is essential to support the continued use of aggressive treatment. Documentation of failure to respond to the initial regimen permits an early change of therapy or the institution of palliative care when appropriate. The original abnormalities in both imaging and CSF studies should be carefully assessed for evidence of response or progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CSF cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of CSF cytology is an important component of response assessment during IT therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/10\">",
"     10",
"    </a>",
"    ]. If possible, CSF should be sampled at each site (lumbar and ventricular) from which malignant cells were originally identified to demonstrate normalization of cytology. Because differences in response in ventricular and lumbar fluid are common, absence of malignant cells in the ventricular compartment does not guarantee resolution of previously documented malignancy within the lumbar CSF. In the context of clinical trials, many investigators require two successive negative evaluations from each site before reporting a cytologic response. In clinical practice, the requirement for multiple LPs in patients who do not have ventricular reservoirs can be problematic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of chromosomal abnormalities by interphase cytogenetics using fluorescence in situ hybridization (FISH) may be useful for patients with known cytologic abnormalities in cells present in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/11\">",
"     11",
"    </a>",
"    ]. Similarly, CSF flow cytometry or serial immunocytochemical staining may be useful in patients with lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H6054645#H6054645\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Molecular techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biomarkers that are specific to the tumor (for example CA-125 for epithelial ovarian cancer) may be quite helpful (",
"    <a class=\"graphic graphic_table graphicRef81558 \" href=\"UTD.htm?35/56/36747\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link&amp;anchor=H1010278#H1010278\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\", section on 'Tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These approaches may be more sensitive than routine cytological examination in detecting residual malignant cells in the CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT appears to be more effective at relieving symptoms than does IT chemotherapy. As a result, our standard treatment for leptomeningeal metastases includes palliative RT (30 to 36 Gy in 3 Gy daily fractions) to sites of symptomatic or bulky disease. In addition, we suggest administering RT to sites of obstruction of CSF flow, as demonstrated by a radionuclide CSF flow study, prior to IT chemotherapy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pretreatment CSF flow study'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To avoid excess myelosuppression and other toxicity such as severe fatigue, esophagitis, diarrhea, and nausea, focal rather than craniospinal RT is preferred. Radiation is usually targeted to symptomatic areas even in the absence of MRI abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial irradiation is used in patients with isolated cranial neuropathies or focal collections of malignant cells causing noncommunicating hydrocephalus. Shunting of CSF should be performed in patients with symptomatic or communicating hydrocephalus that does not clear rapidly with treatment.",
"     </li>",
"     <li>",
"      Occasionally, patients with cytology-proven carcinomatous meningitis and symptomatic communicating hydrocephalus undergo CSF shunting, but the site of CSF flow disturbance remains occult radiographically (eg, enhanced brain and spine MR are negative and Indium 111 studies cannot be performed after VPS). Since communicating hydrocephalus can be caused by malignant cells in the subarachnoid space obstructing normal CSF resorption pathways, whole brain radiation therapy may be appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/12\">",
"       12",
"      </a>",
"      ]. Alternatively, skull base radiation using 2.5 Gy in 10 fractions may resolve the block, while allowing for subsequent brain irradiation, if it becomes necessary.",
"     </li>",
"     <li>",
"      Patients with lower extremity weakness, or bladder or bowel dysfunction, generally receive lumbosacral spine irradiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Major adverse effects during or after focal RT alone are unusual. However, with more extensive fields, major effects of RT may include myelosuppression, mucositis, esophagitis, and leukoencephalopathy. Leukoencephalopathy may be especially prominent when cranial RT is administered prior to or concurrently with IT or systemic chemotherapy, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Although many patients do not live a long enough to suffer the delayed effects of radiation therapy, some do. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H20#H20\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal neurologic deficits generally do not improve although RT frequently alleviates radicular pain and encephalopathic symptoms. However, RT may delay or prevent the development of new neurologic deficits. In addition, involved-field RT can restore normal CSF flow dynamics if it reduces the bulky disease responsible for CSF obstruction. Most good-risk patients also receive IT chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTRATHECAL CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal (IT) chemotherapy is the mainstay of treatment for leptomeningeal metastases, although its effectiveness may be limited and its superiority compared to systemic treatment has not been established in randomized trials. Currently, three drugs are used for IT chemotherapy:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    , and less often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    . Experimental agents including monoclonal antibodies are assuming increasing importance and are discussed below.",
"   </p>",
"   <p>",
"    The role for intrathecal therapy in leptomeningeal metastases from lymphoma and leukemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Leptomeningeal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intraventricular versus intralumbar treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;IT chemotherapy involves the injection of antitumor agents into the CSF, either directly into the lateral ventricle through a subcutaneous reservoir and ventricular catheter (eg, an Ommaya device) or into the lumbar thecal sac by lumbar puncture (LP). If a ventricular catheter is placed, it is important to check for correct placement before chemotherapy is initiated as administration of drug into the brain parenchyma may cause focal leukoencephalopathy. IT chemotherapy is more likely to be effective for small leptomeningeal deposits and individual tumor cells floating in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It cannot reliably treat bulky disease, because diffusion of drug into tumor deposits thicker than 1 mm, along nerve root sleeves, and into the Virchow-Robin spaces is limited.",
"   </p>",
"   <p>",
"    Intraventricular as opposed to intralumbar IT administration by LP offers several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent LP is difficult for both the patient and physician, and results in the inadvertent introduction of drug into the epidural or subdural space in as many as 10 percent of administrations [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Even in the absence of obstruction to CSF flow, administration of chemotherapy via LP results in unpredictable drug concentrations in the ventricles and over the brain convexities [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/16\">",
"       16",
"      </a>",
"      ]. Drug levels in the ventricular CSF following LP are only one-tenth those achieved after an equivalent intraventricular dose. In contrast, administration through an Ommaya reservoir permits more uniform drug distribution throughout the neuraxis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A survival benefit was suggested for intraventricular compared to lumbar IT chemotherapy by observational data, perhaps as a consequence of these issues [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Others have suggested a progression-free survival benefit for intraventricular administration in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . Ventricular administration was compared to lumbar administration in a subset analysis of a randomized trial comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"       liposomal cytarabine",
"      </a>",
"      with methotrexate in 100 patients with neoplastic meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/18\">",
"       18",
"      </a>",
"      ]. Overall, intrathecal chemotherapy was given into the ventricles in 72 percent of cases and by lumbar puncture in 28 percent. For patients given liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , there was no statistically significant difference based upon the route of administration. For those treated with intrathecal methotrexate, the ventricular route appeared preferable (progression-free survival 19 versus 43 days, p=0.048). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Liposomal cytarabine'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Methotrexate'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether the magnitude of these advantages is sufficient to outweigh the risks of surgery for reservoir placement and the increased risk of infection is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .) Nevertheless, whenever possible, we recommend that IT chemotherapy be administered through a subcutaneous reservoir and ventricular catheter directly into the lateral ventricle (eg, an Ommaya device), rather than by LP. Repeat LP is required in patients who unable or unwilling to undergo surgical placement of a reservoir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Technique of CSF administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful attention to minimizing any change in CSF volume with IT therapy is critical. Serious complications (eg, headache, nausea and vomiting, obtundation, herniation) can develop acutely if the total volume is increased even in asymptomatic patients with leptomeningeal metastases, because they may be on the edge of their CSF ventricular compliance (\"pressure-volume\") curve. Thus, equivalent volumes of CSF (usually 7 to 10 mL) should be removed prior to instilling intrathecal (IT) chemotherapy.",
"   </p>",
"   <p>",
"    Conversely, decreases in CSF volume can cause patients to develop a pressure sensation (usually frontal or retroorbital) during the withdrawal of large volumes of CSF from the ventricles. This sensation disappears promptly after fluid is replaced during the chemotherapy infusion and is less common if the procedure is performed with the patient supine.",
"   </p>",
"   <p>",
"    Administration of intraventricular chemotherapy follows a standard procedure. After sterile preparation of the skin with Betadine, a 23-gauge butterfly needle attached to a three-way stopcock is inserted into the ventricular reservoir. Approximately 15 to 20 mL of CSF are then withdrawn gradually over two to five minutes (depending upon patient tolerance) into syringes no larger than 10 mL. Syringes should be partially opened and closed prior to their attachment to the stopcock. The first 10 mL syringe is left attached to the stopcock and is used to flush the chemotherapy through the butterfly needle and Ommaya catheter following drug administration. The remaining CSF is sent for cytology and other studies.",
"   </p>",
"   <p>",
"    Once the CSF has been withdrawn, the syringe containing the drug is attached to a stopcock port. The port pointing to the ceiling is best, to avoid injecting air into the ventricle. A small amount of CSF is withdrawn into the syringe to ensure continued correct placement of the butterfly needle. The chemotherapy is then administered slowly, generally over two to three minutes. In some patients, particularly those with small ventricles or an elevated intracranial pressure (ICP), a slower rate of administration is necessary to avoid headache.",
"   </p>",
"   <p>",
"    CSF from the original 10 mL syringe is then drawn into the chemotherapy syringe by repositioning the stopcock and subsequently injected through the reservoir over two to three minutes, in order to flush any drug remaining in the chemotherapy syringe or reservoir into the ventricular system. The needle is then removed, and light pressure is applied with a sterile 4 x 4 gauze pad.",
"   </p>",
"   <p>",
"    The use of IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (15 to 30 mg) in conjunction with IT chemotherapy was popularized in the 1970s and thought to reduce toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there are no controlled trials proving benefit, and most investigators do not use IT glucocorticoids for patients receiving water-soluble",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or other intrathecal chemotherapy. The use of oral glucocorticoids in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Liposomal cytarabine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8718854\">",
"    <span class=\"h3\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An Ommaya reservoir may be accessed with a platelet count as low as",
"    <span class=\"nowrap\">",
"     20,000/microL,",
"    </span>",
"    although special precautions are necessary, such as gently handling the syringe and taking care not to exert too much force in withdrawing fluid. However, administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    if the platelet count is below",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    is NOT recommended. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Myelosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is the chemotherapeutic agent most commonly used for IT therapy in leptomeningeal metastases. It is active against breast cancer and hematologic malignancies, but is less active against other solid tumors such as lung cancer and sarcoma. In the CSF, MTX has a half-life of 4.5 hours, declining to subtherapeutic levels within four days.",
"   </p>",
"   <p>",
"    A standard induction regimen consists of a fixed dose of 10 or 12 mg twice weekly for four weeks. For IT use, preservative free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is diluted to a concentration of up to 4",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    in an appropriate sterile, preservative free medium such as 0.9 percent sodium chloride injection, USP. The technique for CSF administration is discussed above. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Technique of CSF administration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If no response is seen, therapeutic options include another four weeks of induction therapy or a trial with an alternative agent. If clinical response occurs, the frequency of administration is decreased to weekly for four to eight weeks, and then a maintenance regimen is continued with drug administration every two weeks for several months, and then monthly for two to four months. The optimal duration of therapy in responding patients is uncertain; however, treatment beyond six months may be unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Response evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    MTX successfully clears malignant cells from the CSF in 20 to 61 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The clinical efficacy of IT MTX in conjunction with RT is illustrated by several retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In one report, median survival ranged from three months in patients with breast cancer to eight months in those with lymphoma, although responding patients occasionally survived substantially longer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/23\">",
"     23",
"    </a>",
"    ]. In another series, patients who responded to treatment by the end of one month exhibited a median additional survival of six months, while those not responding survived an additional two months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Myelosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous exposure to low systemic concentrations of MTX can cause severe myelosuppression. MTX is not metabolized in the CSF. It is absorbed slowly by the choroid plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/26\">",
"     26",
"    </a>",
"    ], released into the systemic circulation, and then excreted by the kidneys.",
"    <br/>",
"   </p>",
"   <p>",
"    The risk of serious myelosuppression is increased in patients with one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal insufficiency, resulting in delayed excretion of MTX",
"     </li>",
"     <li>",
"      Pleural effusion or ascites, which can accumulate MTX and then slowly release drug into the systemic circulation (the \"third space\" effect)",
"     </li>",
"     <li>",
"      Abnormal CSF flow, prolonging release of MTX from the CSF into the systemic circulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MTX is partially bound to serum albumin. Thus, toxicity can be increased when drugs that displace MTX from albumin are coadministered (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , sulfonamides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To minimize the risk of systemic MTX toxicity, we routinely give concurrent oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (10 mg twice daily for three days) to all patients to minimize myelosuppression related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    leaving the CSF and entering the bloodstream before being eliminated by the kidneys. Leucovorin does not cross the blood brain barrier and does not affect the activity of MTX against LM. Thus, it may be started at the same time as the IT MTX.",
"   </p>",
"   <p>",
"    We do not administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to patients with a platelet count",
"    <span class=\"nowrap\">",
"     &le;50,000/microL.",
"    </span>",
"    If the platelet count is between 50,000 and",
"    <span class=\"nowrap\">",
"     150,000/microL,",
"    </span>",
"    we give higher than usual doses of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (10 mg four times daily for three days).",
"   </p>",
"   <p>",
"    Most American patients receive a racemic mixture of d,l-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    . However, the l-isomer is the biologically active moiety, and a preparation of l-leucovorin is now commercially available in the US (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/63/14326?source=see_link\">",
"     levoleucovorin",
"    </a>",
"    ). It is dosed at one-half that of d,l-leuvovorin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Neurologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of neurologic complications can result from IT MTX therapy. These include chemical (aseptic) meningitis, delayed leukoencephalopathy, acute encephalopathy, and transverse myelopathy. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H10#H10\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'IT MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive accidental overdose with IT MTX must be treated vigorously since it can cause acute myelopathy, encephalopathy, and death. Patients with significant overdoses are treated with the combination of intrathecal administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    (carboxypeptidase G2, CPDG2) to metabolize the MTX, and ventriculolumbar perfusion to reduce the amount of MTX in the CSF. The approach to such overdoses in discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H11#H11\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Management of accidental overdose of IT MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Liposomal cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     Cytarabine",
"    </a>",
"    has been used for IT therapy in both a conventional formulation and encapsulated within liposomes (DepoCyt).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     Liposomal cytarabine",
"    </a>",
"    is the preferred formulation in patients with leptomeningeal metastases due to solid tumors. Conventional cytarabine is relatively ineffective in such patients, and its use is usually restricted to those with leptomeningeal metastases from leukemia or lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The conventional formulation has a half-life of less than four hours in the CSF and is entirely eliminated within one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    maintains a therapeutic concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in the CSF for up to 28 days. The usual liposomal cytarabine regimen is 50 mg IT every two weeks, with the frequency of administration decreasing in responding patients. The drug is provided in a single-use vial and does not contain any preservative; dilution is not needed. Technique of CSF administration is reviewed above. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Technique of CSF administration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     Liposomal cytarabine",
"    </a>",
"    has been compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in two small trials in patients with leptomeningeal metastases from both solid tumors and hematologic malignancies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 61 patients with leptomeningeal metastases from various solid tumors were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"       liposomal cytarabine",
"      </a>",
"      or IT MTX [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. There was a statistically significant delay in the time to neurologic progression (58 versus 30 days, with IT MTX), and there was a nonsignificant trend toward increased median survival (105 versus 78 days). The improvement in neurologic progression-free survival was associated with a modest increase in toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second trial, 100 solid tumor patients were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"       liposomal cytarabine",
"      </a>",
"      or MTX [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/18\">",
"       18",
"      </a>",
"      ]. Overall there was no significant difference in the progression-free survival with the two agents (35 and 37.5 days, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies also provide some evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    . As an example, in a nonrandomized series, 12 of 43 women with LM from breast cancer had a negative CSF cytology following treatment, a rate similar to other IT agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     Liposomal cytarabine",
"    </a>",
"    appears to be more effective than conventional IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in patients with leptomeningeal metastases from lymphoma, as assessed by the rate of complete tumor clearance, time to neurologic progression, and survival. The use of liposomal cytarabine in leptomeningeal metastases for hematologic malignancies is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Leptomeningeal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reduced frequency of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    administration is an important advantage, although this benefit may be partially offset by an increased incidence of chemical meningitis. To minimize this complication,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    should be administered orally (4 mg twice daily) for a total of five days, preferably initiating therapy one day before and continuing for four days after liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    instillation. Less common neurologic complications of both the conventional and liposomal formulations of IT cytarabine include encephalopathy, seizures, myelopathy, and a pseudotumor cerebri-like syndrome. These are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H28#H28\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Thiotepa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     Thiotepa",
"    </a>",
"    is highly lipid soluble, rapidly diffuses out of the CSF, and has the shortest half-life of the agents used for IT chemotherapy. Infusion of 1 mg of thiotepa results in a peak CSF concentration of 100",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    decreasing to 10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    after one hour; the drug is completely eliminated from the CSF within four hours.",
"   </p>",
"   <p>",
"    IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    is well tolerated in the CNS (myelopathy is only rarely reported), but does cause systemic myelosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/21\">",
"     21",
"    </a>",
"    ]. The usual regimen is 10 mg intrathecally on the same twice weekly schedule as MTX, with subsequent reductions in dose in responding patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/21,32\">",
"     21,32",
"    </a>",
"    ]. Thiotepa has been used in patients who have failed MTX, have MTX-induced leukoencephalopathy, or who need concurrent brain radiation.",
"   </p>",
"   <p>",
"    The efficacy of IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    is not as well established as that of IT MTX. In a prospective, randomized comparison in 59 patients with leptomeningeal metastases, a low performance status, and positive cytology, complete cytologic clearance was seen in about one-third of patients treated with each agent and median survivals were similar (14 versus 16 weeks with IT MTX) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/21\">",
"     21",
"    </a>",
"    ]. However, other observational series have failed to show significant clinical benefit from IT thiotepa. In a report of 15 children, for example, no activity was seen using IT thiotepa to treat leptomeningeal metastases from various primary brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of these efficacy concerns, IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    for leptomeningeal metastases has largely been abandoned in favor of IT MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of agents administered IT have been used in patients with leptomeningeal metastases from solid tumors, although their superiority to single agent therapy is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In a nonrandomized study, 55 patients were treated with either MTX or MTX plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/35\">",
"     35",
"    </a>",
"    ]. Combination therapy was associated with a higher cytologic response rate (38 versus 14 percent) and longer median survival (19 versus 10 weeks). However, this apparent benefit could reflect the preferential use of combination therapy in better risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SYSTEMIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several chemotherapy agents provide therapeutic concentrations within the CSF when given in appropriate doses. This fact has been exploited in regimens for hematologic malignancies to simultaneously treat both systemic and leptomeningeal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Leptomeningeal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic chemotherapy offers several theoretical advantages compared to IT therapy in patients with leptomeningeal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risks of surgery for placement of a ventricular reservoir and of reservoir-associated complications are obviated.",
"     </li>",
"     <li>",
"      Patients with an obstruction to normal CSF flow can be treated without correction of the flow abnormality.",
"     </li>",
"     <li>",
"      A wider array of cytotoxic agents can be administered.",
"     </li>",
"     <li>",
"      Systemic chemotherapy may provide more uniform drug distribution, and bulky disease may respond because drug is delivered both via the CSF and through the arterial circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with systemic chemotherapy could theoretically allow the simultaneous treatment of active systemic and leptomeningeal disease. However, the blood-brain-barrier is normal or only partially disrupted in leptomeningeal disease, so studies of systemic therapy have focused on agents that are either lipid-soluble or that can be given safely at high doses. Whether the combination of systemic and intrathecal drug is better than systemic drug alone remains poorly studied. The only trial to address this question included breast cancer patients with leptomeningeal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/36\">",
"     36",
"    </a>",
"    ]. In this small trial, women were randomly assigned to receive (n = 17) or not receive (n = 18) IT MTX. Systemic therapy and RT was given as deemed appropriate to all patients. No significant difference in neurologic condition, or median survival was seen. However, treatment-related neurological complications were significantly more frequent in the IT therapy group (47 versus 6 percent, p=0.0072).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     High-dose MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic administration of high-dose MTX with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue is the most widely used alternative to IT chemotherapy. The results of studies assessing the effectiveness of high-dose MTX in patients with LM from solid tumors have been mixed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, for example, patients with LM from solid tumors were treated with high-dose MTX (8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/22\">",
"       22",
"      </a>",
"      ]. Cytologic clearing of tumor cells occurred in 13 of 16 patients compared with 9 of 15 historical controls treated with IT MTX. Cytotoxic CSF MTX levels were consistently achieved.",
"     </li>",
"     <li>",
"      In contrast, objective antitumor responses were not seen in another series despite achieving therapeutic CSF MTX levels with lower MTX doses (700",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      initially, followed by a 23-hour infusion of 2800",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-dose MTX requires hospitalization for hydration, urinary alkalinization, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue to avoid systemic MTX toxicity. If patients develop early renal insufficiency and plasma MTX levels remain high for a prolonged period despite these measures, early treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    (carboxypeptidase G2, CPDG2) to metabolize the MTX is crucial to preventing severe toxicity and death. The use of high-dose MTX and crystal-induced renal failure in patients treated with MTX are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link&amp;anchor=H36#H36\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Alternative rescue techniques for patients with renal failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If prolonged high levels of MTX are observed, but additional cycles of high-dose MTX are clinically necessary, methylene-tetrahydrofolate reductase (MTHFR) genotyping may be useful to identify individuals with diminished MTHFR activity who are at increased risk of MTX toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the appropriate intervention, reduced doses of MTX, would be carried out even if genotyping did not a reveal a slow recovery phenotype. Thus, the role of MTHFR genotyping remains uncertain. Routine prospective MTHFR genotyping prior to the first dose of high-dose MTX is not recommended.",
"   </p>",
"   <p>",
"    The use of high-dose MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue to treat lymphomatous LM is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Leptomeningeal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     High-dose cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following systemic administration, the concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in the CSF is approximately 6 to 22 percent of that in the serum [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Therapeutic CSF levels can be achieved by administering cytarabine 3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/41\">",
"     41",
"    </a>",
"    ], or by continuous intravenous infusion of doses &gt;4",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/42\">",
"     42",
"    </a>",
"    ]. However, systemic administration of high-dose cytarabine is associated with significant toxicity, including severe myelosuppression, cerebellar toxicity, nausea, vomiting, and mucositis, and this approach has not proven useful in the treatment of LM from solid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H28#H28\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic administration of a number of other agents has resulted in clinical benefit in small series or case reports. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       Capecitabine",
"      </a>",
"      &ndash; Capecitabine, an oral prodrug of 5-fluorouracil, has induced responses and disease stabilization in several patients with LM from breast and lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/43-47\">",
"       43-47",
"      </a>",
"      ]. Additional clinical experience is required to determine the utility of this agent.",
"     </li>",
"     <li>",
"      EGFR tyrosine kinase inhibitors &ndash; The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      have activity in patients with NSCLC. This activity is most evident in women, nonsmokers, patients of Asian ethnicity, those with adenocarcinoma, and those with specific mutations of the EGFR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link&amp;anchor=H9#H9\">",
"       \"Systemic therapy for brain metastases\", section on 'Targeted agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link&amp;anchor=H177151213#H177151213\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\", section on 'EGFR mutation as predictor of responsiveness'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In an observational series, 11 patients with LM from NSCLC were treated with erlotinib 150 mg daily, based upon predicted sensitivity to this class of agent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/48\">",
"       48",
"      </a>",
"      ]. Nine of the 11 appeared to benefit, as manifested by an improvement in performance status.",
"      <br/>",
"      <br/>",
"      In other case reports, patients with LM from adenocarcinoma of lung improved clinically and radiographically after treatment with standard dose [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/49-52\">",
"       49-52",
"      </a>",
"      ] or high-dose [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/48,53\">",
"       48,53",
"      </a>",
"      ]gefitinibTwo reports observed a good response using erlotinib at a higher dose (600 mg daily, and high dose weekly treatment (1500 mg), respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL INTRATHECAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited effectiveness of currently available agents for IT administration has led to the evaluation of several alternatives. These include diaziquone (AZQ) in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/56\">",
"     56",
"    </a>",
"    ], and mafosfamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , interferon alfa, and monoclonal antibodies in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Mafosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mafosfamide is a chemically stable salt of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    that does not require hepatic bioactivation. Thus, unlike cyclophosphamide, it can be administered directly into the CSF. IT mafosfamide is being clinically evaluated primarily in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. As an example, in a phase I study of 36 patients with either acute lymphoblastic leukemia or medulloblastoma, partial responses were observed in 24 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/57\">",
"     57",
"    </a>",
"    ]. Additional studies are required to define the clinical role of mafosfamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other chemotherapy agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three reports have evaluated IT",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    for LM [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/58,60,61\">",
"     58,60,61",
"    </a>",
"    ]. Treatment was well tolerated, but there are inadequate data to draw any conclusions regarding its relative efficacy. Other chemotherapy agents that have been evaluated IT include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/62\">",
"     62",
"    </a>",
"    ], nitrosoureas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/63\">",
"     63",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/64\">",
"     64",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/65\">",
"     65",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal monoclonal antibodies have been used to deliver radionuclides as an alternative to external beam radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In addition, systemically active monoclonal antibodies have been administered intrathecally to control refractory LM. Evidence of antitumor activity has been observed with this approach, using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (20 to 25 mg IT per week) in patients with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/69-73\">",
"     69-73",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for leptomeningeal metastases from lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/74-78\">",
"     74-78",
"    </a>",
"    ]. Reconstitution for intrathecal use should be with preservative-free products [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Leptomeningeal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy using IT interleukin-2 (IL-2) has been studied in patients with LM from disseminated melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. In a preliminary report, 46 patients were treated with IT IL-2, 1.2 million units daily for five days, and then two to three times weekly as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/82\">",
"     82",
"    </a>",
"    ]. Twelve patients responded with two still alive beyond 32 and 90 months, respectively. Significant toxicities included fever, chills, and elevated ICP, which was relieved by removal of CSF via the Ommaya reservoir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite aggressive therapy, even good-risk patients with LM usually have a limited survival as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 59 patients with solid tumors treated with either intrathecal MTX or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      , 75 percent progressed within the first eight weeks of therapy and no patient had meaningful improvement of neurologic deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In four randomized controlled clinical trials using currently available CNS chemotherapeutic agents, median survival in carefully selected patients was only three to four months (",
"      <a class=\"graphic graphic_table graphicRef62241 \" href=\"UTD.htm?20/15/20731\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/17,21,29,84\">",
"       17,21,29,84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delayed diagnosis, irreversible neurologic deficits at the time of diagnosis, and extensive disease outside the CNS all can contribute to the observed poor outcome.",
"   </p>",
"   <p>",
"    Tumor histology may be an important factor influencing prognosis. As an example, the median survival is six to seven months for women with breast cancer who are treated aggressively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/36,85\">",
"     36,85",
"    </a>",
"    ]. In contrast, patients with leptomeningeal spread of high-grade gliomas do particularly poorly; median survival is approximately three months even with aggressive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/1\">",
"     1",
"    </a>",
"    ], while those with secondary gliomatosis from low-grade astrocytomas appear to have a longer survival and may benefit from chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performance status and systemic disease burden are important prognostic factors. Prognosis generally is better for younger patients with a good Karnofsky performance status (KPS) (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ), long duration of pretreatment symptoms, and well-controlled extraneural disease compared to those with adverse prognostic factors (eg, advanced age, poor KPS, rapidly progressive neurologic or cognitive deficits, bulky subarachnoid disease on neuroimaging studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/53/26458/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the poor prognosis in the majority of patients with LM, sustained tumor control is reported in a small subset with favorable characteristics. Such observations provide the primary rationale for aggressive treatment of good-risk patients with low tumor burden (ie, minimal bulky disease in the brain or subarachnoid space).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment include symptom palliation, improving or stabilizing neurologic function, and prolonging survival. The prognosis varies considerably, depending upon the extent of both neurologic and systemic disease. The appropriate therapeutic approach for an individual patient is dependent upon these risk factors (",
"    <a class=\"graphic graphic_table graphicRef54352 \" href=\"UTD.htm?6/44/6859\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Goals of treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Good-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a good performance status, no or modest fixed neurologic deficits, and minimal systemic disease burden or a cancer for which there are reasonable treatment options, we suggest an aggressive approach that includes control of increased intracranial pressure (ICP), radiation therapy (RT) to areas of bulky disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstructed cerebrospinal fluid (CSF) flow, and intrathecal (IT) or high-dose chemotherapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Good-risk patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased ICP &ndash; We recommend corticosteroid treatment (generally",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) for the initial management of increased ICP (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Increased ICP'",
"      </a>",
"      above.) Dexamethasone, 8 mg twice a day, is usually effective. Treatment should be started promptly and the dose reduced as quickly as possible until the lowest effective dose is achieved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A ventriculoperitoneal shunt should be avoided unless increased intracranial pressure cannot be controlled with corticosteroids. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Increased ICP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antitumor treatment &ndash; For good-risk patients, we recommend antitumor treatment of the leptomeningeal metastases (LM) with RT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy in conjunction with treating increased ICP (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prior to beginning treatment, performing a CSF flow study via a radionuclide cisternogram may define areas of obstruction to CSF flow. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pretreatment CSF flow study'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest RT for the initial management of areas of bulky or symptomatic disease and to treat any obstructions to CSF flow (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Focal, rather than craniospinal, RT is preferred to avoid excess myelosuppression. Our usual dose and schedule is 30 to 36 Gy in 3 Gy daily fractions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with LM but",
"      <strong>",
"       without",
"      </strong>",
"      bulky disease, as documented by an MRI that is negative or shows linear enhancement only and without focal neurological symptoms, we recommend IT chemotherapy rather than RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Intrathecal chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We prefer to administer IT chemotherapy via an Ommaya reservoir rather than by lumbar puncture whenever possible. Meticulous attention to the technique of chemotherapy administration is required. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intraventricular versus intralumbar treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Technique of CSF administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When placement of an Ommaya reservoir is difficult or impossible, systemic chemotherapy with high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) is an alternative. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'High-dose MTX'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest IT MTX as the preferred agent for patients with LM from solid tumors (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Our induction regimen consists of a dose of 10 to 12 mg twice a week. After four weeks, the frequency of treatment is tapered to weekly and then every other week in responding patients. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest administering oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (10 mg orally twice daily for three days) to all patients receiving IT MTX to prevent systemic MTX toxicity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Myelosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom a less frequent treatment schedule is an important consideration, IT",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/53/34645?source=see_link\">",
"       liposomal cytarabine",
"      </a>",
"      (50 mg every two weeks) is an alternative. To minimize the risk of chemical meningitis, we administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (4 mg orally twice daily) for two days before and two days after IT liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Liposomal cytarabine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For good-risk patients with",
"      <strong>",
"       bulky",
"      </strong>",
"      LM, we suggest systemic chemotherapy with high-dose MTX (3 to 8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      rather than IT chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). MTX must be accompanied by aggressive hydration and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'High-dose MTX'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of response &mdash; Clinical signs and symptoms, quantitative measures of tumor markers within the CSF, CSF cytology, and radiographic studies should be monitored closely during treatment. Failure to clear malignant cells from the CSF within four to eight weeks after initiating chemotherapy or worsening clinical parameters indicates a need to alter therapy or reconsider therapeutic objectives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CSF should be sampled from the site that was previously positive; lumbar specimens should be considered separately from ventricular specimens. Because differences in response in ventricular and lumbar fluid are common, absence of malignant cells in the ventricular compartment is no guarantee that previously documented malignancy within the lumbar CSF has resolved. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Response evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Poor-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For poor-risk patients (ie, a poor performance status, significant fixed neurologic deficits,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of advanced systemic disease without good therapeutic options) (",
"    <a class=\"graphic graphic_table graphicRef54352 \" href=\"UTD.htm?6/44/6859\">",
"     table 1",
"    </a>",
"    ), treatment should focus on symptom palliation. We suggest not using IT chemotherapy. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Poor-risk patients'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/1\">",
"      Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 2003; 52:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/2\">",
"      Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology 2004; 63:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/3\">",
"      Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983; 1:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/4\">",
"      Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005; 64:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/5\">",
"      Lee SH, Kong DS, Seol HJ, et al. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neurooncol 2011; 104:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/6\">",
"      Rickert CH. Abdominal metastases of pediatric brain tumors via ventriculo-peritoneal shunts. Childs Nerv Syst 1998; 14:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/7\">",
"      Grossman SA, Trump DL, Chen DC, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 1982; 73:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/8\">",
"      Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991; 41:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/9\">",
"      Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995; 75:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/10\">",
"      Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/11\">",
"      van Oostenbrugge RJ, Hopman AH, Arends JW, et al. Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J Clin Oncol 2000; 18:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/12\">",
"      Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep 2003; 5:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/13\">",
"      Grossman SA, Reinhard CS, Loats HL. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol 1989; 7:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/14\">",
"      Burch PA, Grossman SA, Reinhard CS. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study. J Natl Cancer Inst 1988; 80:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/15\">",
"      Larson SM, Schall GL, Di Chiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med 1971; 12:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/16\">",
"      Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/17\">",
"      Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/18\">",
"      Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010; 116:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/19\">",
"      Sullivan MP, Moon TE, Trueworthy R, et al. Combination intrathecal therapy for meningeal leukemia: two versus three drugs. Blood 1977; 50:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/20\">",
"      Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/21\">",
"      Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/22\">",
"      Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998; 16:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/23\">",
"      Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases--treatment results in 98 consecutive patients. Isr J Med Sci 1988; 24:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/24\">",
"      Sause WT, Crowley J, Eyre HJ, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases--a Southwest Oncology Group study. J Neurooncol 1988; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/25\">",
"      Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/26\">",
"      Rubin R, Owens E, Rall D. Transport of methotrexate by the choroid plexus. Cancer Res 1968; 28:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/27\">",
"      Fulton DS, Levin VA, Gutin PH, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 1982; 8:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/28\">",
"      Esteva FJ, Soh LT, Holmes FA, et al. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 2000; 46:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/29\">",
"      Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5:3394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/30\">",
"      Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003; 97:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/31\">",
"      Jaeckle KA, Phuphanich S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001; 84:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/32\">",
"      Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 1977; 61:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/33\">",
"      Fisher PG, Kadan-Lottick NS, Korones DN. Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol 2002; 24:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/34\">",
"      Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998; 55:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/35\">",
"      Kim DY, Lee KW, Yun T, et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 2003; 33:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/36\">",
"      Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004; 40:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/37\">",
"      Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000; 46:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/38\">",
"      Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/39\">",
"      Slevin ML, Piall EM, Aherne GW, et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983; 1:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/40\">",
"      Lopez JA, Nassif E, Vannicola P, et al. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 1985; 3:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/41\">",
"      Frick J, Ritch PS, Hansen RM, Anderson T. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 1984; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/42\">",
"      Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986; 70:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/43\">",
"      Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 2003; 65:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/44\">",
"      Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol 2004; 6:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/45\">",
"      Shigekawa T, Takeuchi H, Misumi M, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 2009; 16:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/46\">",
"      Ekenel M, Hormigo AM, Peak S, et al. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007; 85:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/47\">",
"      Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 2006; 7:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/48\">",
"      Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009; 65:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/49\">",
"      Kanaji N, Bandoh S, Nagamura N, et al. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Intern Med 2007; 46:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/50\">",
"      Sakai M, Ishikawa S, Ito H, et al. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol 2006; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/51\">",
"      Hashimoto N, Imaizumi K, Honda T, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer 2006; 53:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/52\">",
"      So T, Inoue M, Chikaishi Y, et al. Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases. Surg Today 2009; 39:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/53\">",
"      Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006; 24:4517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/54\">",
"      Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 2009; 27:e31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/55\">",
"      Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/56\">",
"      Berg SL, Balis FM, Zimm S, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992; 10:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/57\">",
"      Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 2005; 23:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/58\">",
"      Slavc I, Schuller E, Falger J, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003; 64:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/59\">",
"      Blaney SM, Boyett J, Friedman H, et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol 2005; 23:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/60\">",
"      Fleischhack G, Reif S, Hasan C, et al. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 2001; 84:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/61\">",
"      Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 2006; 106:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/62\">",
"      Champagne MA, Silver HK. Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma. J Natl Cancer Inst 1992; 84:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/63\">",
"      Kochi M, Kuratsu J, Mihara Y, et al. Neurotoxicity and pharmacokinetics of intrathecal perfusion of ACNU in dogs. Cancer Res 1990; 50:3119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/64\">",
"      Gururangan S, Petros WP, Poussaint TY, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res 2006; 12:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/65\">",
"      Friedman HS, Archer GE, McLendon RE, et al. Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. Cancer Res 1994; 54:4710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/66\">",
"      Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 2008; 10:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/67\">",
"      Brown MT, Coleman RE, Friedman AH, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996; 2:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/68\">",
"      Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neurooncol 1998; 38:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/69\">",
"      Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001; 2:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/70\">",
"      Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006; 15:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/71\">",
"      Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006; 7:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/72\">",
"      Stemmler HJ, Mengele K, Schmitt M, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 2008; 19:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/73\">",
"      Oliveira M, Braga S, Passos-Coelho JL, et al. Complete response in HER2+&nbsp;leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 2011; 127:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/74\">",
"      Schulz H, Pels H, Schmidt-Wolf I, et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/75\">",
"      Antonini G, Cox MC, Montefusco E, et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 2007; 81:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/76\">",
"      Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/77\">",
"      Villela L, Garc&iacute;a M, Caballero R, et al. Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs 2008; 19:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/78\">",
"      Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 2009; 91:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/79\">",
"      Siderov J. Care with intrathecal trastuzumab. Lancet Oncol 2006; 7:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/80\">",
"      Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 1989; 7:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/81\">",
"      Samlowski WE, Park KJ, Galinsky RE, et al. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphasis Tumor Immunol 1993; 13:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/82\">",
"      Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 1998; 38:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/83\">",
"      Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/84\">",
"      Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/85\">",
"      Gauthier H, Guilhaume MN, Bidard FC, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 2010; 21:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/86\">",
"      Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosis cerebri. Neurology 2004; 63:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/87\">",
"      Louis E, Keime-Guibert F, Delattre JY, Sanson M. Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology 2003; 60:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/53/26458/abstract/88\">",
"      DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38:245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5184 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26458=[""].join("\n");
var outline_f25_53_26458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Poor-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Good-risk patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Increased ICP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pretreatment CSF flow study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CSF cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTRATHECAL CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intraventricular versus intralumbar treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Technique of CSF administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8718854\">",
"      - Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Myelosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Neurologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Liposomal cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Thiotepa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SYSTEMIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      High-dose MTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      High-dose cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      INVESTIGATIONAL INTRATHECAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Mafosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Good-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Poor-risk patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5184\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5184|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/44/6859\" title=\"table 1\">",
"      Risk cats patients with LM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/56/36747\" title=\"table 3\">",
"      Cerebrospinal fluid biochemical markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/15/20731\" title=\"table 4\">",
"      Survival in LM patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=related_link\">",
"      Involvement of the central nervous system with acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_53_26459="Signs symptoms breast CA recur";
var content_f25_53_26459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms consistent with breast cancer relapse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Locoregional recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mass in the ipsilateral breast following breast conserving therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mass in the chest wall after mastectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nipple discharge in the treated breast following breast conserving therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rash localized to the treated breast or chest wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Axillary, supraclavicular, infraclavicular, or cervical lymph node enlargement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal relapse: localized, progressive bone pain or tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary metastasis: pleuritic chest pain, cough, dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver relapse: right upper quadrant discomfort, fullness, or pain; weight loss; anorexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS metastasis: persistent headache, mental status changes, new onset seizure, focal motor or sensory loss, bladder or bowel dysfunction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30:338. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26459=[""].join("\n");
var outline_f25_53_26459=null;
var title_f25_53_26460="Pain management strategies for buprenorphine maintained women";
var content_f25_53_26460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pain management strategies for postpartum women on buprenorphine substitution therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preferred strategy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Give the maintenance dose of buprenorphine* plus full opioid agonists",
"          <sup>",
"           &Delta;",
"          </sup>",
"          (eg, patient-controlled-analgesia; intravenous, transdermal, or&nbsp;intramuscular opioids;&nbsp;oral opioids plus acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen, ketorolac). Total daily doses required for opioid analgesia may be 30 to 100 percent higher than usual doses in opioid-na&iuml;ve patients.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alternative strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Give the maintenance dose of buprenorphine plus supplemental 2 to 4 mg doses of sublingual (SL) buprenorphine every 4 to 6 hours in addition to the patient's daily maintenance dose not to exceed 32 mg SL daily.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Give the maintenance dose of buprenorphine in 4 divided doses over 24 hours taking advantage of the analgesic effects of buprenorphine. Additional full agonist opioids can be given as necessary.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Stop buprenorphine prior to surgery and replace with short-acting full agonist opioids titrated to pain and withdrawal. High doses of full agonist opioids in divided doses every three to four hours are needed for the first 24 to 60 hours to compete with the presence of buprenorphine.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ancillary measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Provide intrapartum regional anesthesia, with or without continuation postpartum.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Instill local anesthesia (eg, cesarean incision, laceration repair, assisted delivery).",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Administer clonidine, especially when pain management is complicated by symptoms of withdrawal. Adjunctive clonidine 0.1 to 0.2 mg orally every two to four hours as needed may decrease withdrawal symptoms. Side effects include orthostatic hypotension, sedation, dry mouth and constipation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Usual buprenorphine maintenance doses can be given in two to four divided doses if there is a concern for sedation or respiratory depression due to addition of opioids for analgesia.",
"     <br/>",
"     &Delta; Mixed acting opioid agonists-antagonists such as nalbuphine or butorphanol can precipitate acute withdrawal symptoms and should therefore be avoided.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26460=[""].join("\n");
var outline_f25_53_26460=null;
var title_f25_53_26461="Changes in PD transport over time";
var content_f25_53_26461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Changes in peritoneal dialysis transport over time",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 237px; background-image: url(data:image/gif;base64,R0lGODlhygHtAOYAAP///4CAgAAAAAAz/8DAwEBAQKCz//8AAP/AwP+AgICZ/8DN/0Bm/xAQEP9AQP8QEDAwMHBwcP+goNDQ0LCwsBBA///w8ODg4PDz//9gYFBQUCAgIPDw8P/Q0GBgYP8wMJCQkDBZ/6CgoNDZ/yBN/1Bz/7DA/+Dm//8gIHCN/5Cm/2CA///g4P9QUP9wcP+wsP+QkO8DD58TX88JL7Cw718fnw8v759Tn59AQC8pz8+pz38Zf79soO+zwD8mv68PT79NgL+dz1Azv0A1z9+mwL98r6Bzv185X88ZQJ8yf68/gM9Jb9C5378MP48wMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADKAe0AAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+OoXBPwEF4IXQASgkK+gQWgBBCgUEADAhQYNIAiIcLCiRWMJPfD7F0EACAANBHC4SLIkr4QbCgQYWUAAAQAtX5qcSVOWiAgBNkyE6ZKnTEEEAggd+rOm0aOeCAgoAECDAIISJxAKOjSASqRYs1bS4CEnQwAiBGigIGDDIqFa06plFCBkA4qC/yKEhCBVEdq1ePNququ3r19IfP8KHmwoMOHDgg0jXpxXMePHWh1DnmxUMuXLJS1j3nxQM+fP9zyDHi1PNOnT7UyjXl2O6lXWsNu5bhi7NjvVtnNvw627tzXevoNHAy7c24kFyE8YGsFgAQAMyBeMGMUgBSIDDKZ/I16cm4IB4AcwwEBoRQXyC8IPCEF+U3oFghQYQLRAgfLttLuv+w5fhfhBGFSwgiDpMQBACQOoUIgBJVSHgQH2qXACBgowUIIJgqTAAAMrTLeCePDJB0B9JqzAAIb1KSefChySR6GFGErDnX7Z8CcICQNoZ0COBP5n4yDflaAACQswMEAFAywQQv8FCoTAIwkKpFABCQA4SYKBPh5p5AAnfOcceCHgOOCSTfI4XH40dmNCjIf8aKRzVYYwSHpQInmfIFMKggEGRpI3AogfwreAhkiOOAB8AGTpXApJepmogRiI9ycDCgQqI5ppZoOBlGwa8iOOyp2Q4JxalgDnIP8NYmSPlCqgwAImDHChk4YiqigAXjqaqngFuvrqpZluM0IIDNzZ5gArLICgdQAw2p6hBh6CoArKFjnAIBVUYMACKkB4qAk4Gnrho7gmWW595u5qYLbbdssLB/wMEtBAbGEaLDX+IarId+BBie2ApEZrCAbmDUDCCasKMgKCBpuAgZXhAmBkBeQ6mmv/utH+t3C/neLigUIAQSQRXInMeK8wfJKg3SQ7nnoRWSAD0NFHIY1Usr0nO2OCgM9OYoK+F3HQQEICCBKTT1NVZRXOOS/D6WMaQABAzEcfPQhVQ73WdDPDFgvZQgs19RQAUdnF9NbFqMCkVv20XZci/Sj0UlhjlXXW2WgHg0EJRKYF9kJMORKzzHO9jYjJec+yQAUl9IyVUBt0lRPJoSCeOCxSzpdXTwAEoAEpll/OygkhhGDsWhERQAEEgYsSuuipGLC2X2EtRNAor8Neyt4VuNzXBEIZXjneusuyAAmNE0ZBABcEIPwnuRcPigIVKEhYRy5xBTrx0o9e+sqDNeAB/wRBtT5897XIzixiLhVAgAfmgxI9+pcQ3PtjBUCwgVMf4c49/aQYAfIcd5gJhEQAELCZ6/4HwFB8x3qUIcDzOjGbBq4CYSEA32NEoLQJZqKCFkTFzlJAQMa05G9F8cT8QqgI+3VsMgUAAT8KEIH9LZCFASRWCb92u6XFrxMrxGEh/ANBzmxgaHLRgFVuKERPpEyDm6HAARswgQj0T34MbOIjdraCHWIGXik8nxYzsakKvPAzE9BAAdZIOSyOERNdO91odAK47b3REvmaBQsQwEcWGKIDDkAAACzARwR0oBIOcMEzxIKKIAJwbyqjRQIOQMkDOMAChMjAAzCJgEoeAP8Fh5SEJZ+hgTb6746SWFwXazHJBAAABqMUhAUekAFBdNIBAEDAAzYJgA5kIJGYJIQFfpmABAhylAhIgB+TucxfZuCQL2iBA2AgSxc4wAGuBIAErklNV3igAWukoR1R+YjM3aKVgkDBAUIpgXXaMpYZOAAMWPCADySgnoX4wAFcEE9XjnKSggRoJ+2JzRccoAUu2CcAUPCABLgABQBIqAtaIE9XnFAhPzQEB5bnPHkJ5HZmI2cjhmU6VkjgBYpAJwAccABBAuADHxjELQXRSliiNKGhzOUBatlJf+ISoAAAKEX9CAAWUBSTH3gAAHaZAWUuFQXFjKUviCY3h4hsJyH/Faki1AY0VLwABShAaSJUqk4/sqCi78QlAOIpAaAC9Z2u7CkA/tnSoLaUpYTA60oP0MsWqPMBZ4VqMSXgCg4IRCgiYIQ/APCxhswMJCLJqlYHxjffeZWwi5hkBhBAUUVG9ADB1OkHknmAmHbgoAhgqDA/iYCE+vSVpU2AOhEAy80WE5YJMGgLVioBBLC0AxQ1Zltd4ZQ6NiIA+vtH1TgHFKVpbbJzGmAqehuJSVISqoOgJSE6SUlaBlMC6vxATgUhgQdY8gCvtQBLP0DRgP71puZtASYp+knCDtO8DXXFRNrHwAJsYANSWW5RsCaU50KXepozBQvuOdpMtNOllegt/2cPIFZouKQBzcsoIpTCFKdARQAeFIQj0Ua6DJ5iwpvdxAuyaYl4fpLF0GiACDRwRA0TgivIFYAHwCIWsphFslpVnyksAF6ohjYtIhCBAanIlgN6wGZyQWCIRZzFBvLOsp9ggSYdgNk0jfhex0veKF7gAFoStS8iOOBSxolK6hXxExaQLQpgcOS+hCScplRhlaWHQShywpeoRcxbGrln3Y1QFAhIqgvOfJgI7PgUXy6OC0eBgC6z729rPmUTBTieT1D3MuEMdZ6BWOi8PdATC64nhC+zDwDAS4FiDCGfTMwJFK8aMxD4HAcix2YAnkBtJNwEkcGagDpvhnNL1HT3MP9QIhJU4ESb0PIDuLyaBvRPA59TNuwG5SRK+bkSZDYzbD4GAYkkFhQgTNwIWLSeFJzREnEGK51rw4GPDToU6c7ZCRg0pRUYwIuVAHQLbq3FSD+G2StwdglU8G1MJPoBi9aqwQ9Tn27/itKWFunE/bJuBIXA3QC/BJEJDt2Nr2Xf5iGBv+XYCV+qOlMROLdAej0TPra1mC9AAKM3wewU4GjhDRe2BJL6zEzBCwIaIYAaaW6QZF5TnZ+8ZjETcE38Sn3VyUyAhPuYiIqv5+KkcPkHJGDs7ijlb49moj06kEysa52PjNjjit2eAGles8yeRMHdkSCDHSihB9sdbCF1ngn/IhN9vMFqXkqEAgJYuxEehIQB1fU5bReQPBQoH4IQjEAE2haT7navet7v7oCmGlMRYid74ibwD0iXOhYGSMG2FsByTSBgxdKkpANakNvLh6LnTgJ6JtheSMmfXqZTT8DhYZdm46odGDtKQYMYgCSDbWgFrpp97RHRWrx/AJswQEDZS1EfI30cy5ROvup1d2c2Mp0XO0owIUaAHBW4avrhIVZ1XMWEtgfekK/wayXQbw4DXZ5wb4/AUT8xLyB1M8EQf5QQBEUABD/QBAcwbUvgA2CyISngKtGBCg+ScIxjANtngJjgaJBwdgpBEA8REVjlgL8AgY1ASG3lAOqkd29n/2zI8TNRsiFOAh4b0iqvghyZYAIp0G0MZ4KkcFGZpgitBgJr9lg1A2S7IIOJ0H3mtXu5hXiTAB2w4ioawgA4oiUW4irUIh2JMAIV0m7op4SfEAGi9ghhsWMCljRVYWC5IIMS4AJT53aElwrHsQAQUikbMobPVoYDqHL/5oa9sGsYhjRW01x3+HqxMwCaU158+Hm+EIj2JyGMyAoTIBEEsAFXpAgTcER14WFkA2JUeAt6+ABc+InvAAEQQQBwqFghITk8Vjc/BoN5aImCoEmxKIvu8BTuk2x28TdxUTh3owsymAHiRYz1YG0FQAG8pm3pA4zD9AHjJ42pATZhpGe4AP+BFgBT3eiN7QACBTAWpWBykUCOH5AB54iO6+A5DlGN7/cKENgB8UiP9iBjggA/+dgK+6hd/lgPyGZjm+COjVCQGXeQ8VBuFCBFo8YJDLkIEFheDwmR8AAzAvCI2EiQwKhNG8mR8NA8INB6IbkKVmiS9xABFQk9lLgJLemS9iCQrqePwCgBJWmT7wACQ4NY+FZgM4kJGfkAPemT7cCECnkJ+VaJ81Few6iU7jABbjOQowCBMACLVHkPy9M8U7YXRUkJECiMXWkP2KN0aRdrp1CWH7BzZxkP4kM+yMiWpeCW8xiX69A+79OUmcCQ8ade3KiX9pA/++MRWNkJgfl9eUn/mOpgQAqRQIlJk5ZYjrXkmPggQaawcfHHAv2ImfVAAesYjo8nCvHXAQYJmvMwAWCjkivJCaf5AN2kmvPQFhM5NJs5looQm0lJm/UYOHjohASgQAxYL6EQfxrpm/VAVc6XCBsliiHjgjHZObp5CBnZm8qpDsyJUYq1EDIhhZHli7A5ktmZFlZTh1fjXNVJCDVZnlhxnj0RiQBAYEujmANwA9jpniVhNapYNuJplPeJlPqZFUfnEVJBNz7WjJqwIzfAlQOKFSqYaVFGFwoKoEngoA96Ga+zIzKAoRlKGaHDoYP5oZhhOQZgAzIwoiSqoTN5ojOgoisKopToovIYo5sx/yM0aqOcwR0GkAMxcJk6WqKF1qMxAGNBKqPv6KP5eaSDwRsGUAMxsKRMmhhZtCM8IKVTqhdPmQjtmaWMsaXWSZ5eKqSM0KVjChme8aQ8cKafoRlPKqBseqNn86ZTGaeLIRkGsAMeaqdIaggG0KF1yqeIoRh/CqOC2qeDQAMp2piH2qRoQgMvyqiNSqWJOgM1OqlyKgiQCqSYmhfLk5LH1RA68KOd2hcdQYsgaTajaqSlmhYc8JEAAIXT2TlHEKWtqqVrxmGGQJ84EANOoDTAGqzCOqzEWqzGeqzImqzKuqzM2qzO+qzQGq3JSpp9oau6Wgi8igPSuq3Nukbc+q3K6v+t4DquxSqu5HquwBqcfsGaUkMW2daKU7WeqnCRFimvqUCv8aATFOAU5wavvYCvYlkMAPuX9moRofiRs0qdxDCwmMCwl+CwlgCxFSGxk0CxFVuwObmwGLsWFhsJHeuxG9uOITuZmBEvw2CyJ0utvICywsCyt/qyMBuzMjuzNFuzNuueHMBBIuB4vpCzH7sIVjkIPss8vaCZg8BRrnkL89J4hGCVSYtrS4FAwgCZ/uULF9B8g0BVqXoLwNOE5BYSKgsLFyU1ggCZIzsT7io2DdgLOhGWtUBVV/MPTnG2l3BCraMQHJAQdGsJFMABu8Y5EvEVbfoVegsMrPlfjPQLgzP/CB/Tr7hwrYxVFuXGs7egE//QFh2xtyRRuIX7C0pBPuamuEXTtFK7C5ALhRLBZLsgqwDAmssjuJzBuo/1C6zJFJ3bC4ubZpJpuplWu7HahLjQEY+2nZprERdQFqMoAE+7C/oKnbywD3LzD1D4FgHguLYwAag7nMfbABTwMWtpC06xAULhD/zgvcs7GSKgExtgvb1wsAD5r2DTEEypC0w4NzohPpQ7C3+TH7d7s/77vwAcwAI8wARcwAZ8wAicwAq8wCTKDzbjtJMwAQXAvgy8l4h5vLDLFj2hFMVbwcmgEGaBPbShjuzYOSKgjk92AS3hASKgFDD5GhMAPxpAwR7ssg1l8RQNoBOONRGqGJk64QGniEARcHYFEBIicLwQEAAe8K41HA5LoQEQUbgR4WqMtGavarsb/BVk4TxlYUX528TbsBRkgRNfkWlrZsZY/BIcPJ9aXMSlC8bgkKt5+xUelhAfgcadwxD88BUc/D4UQAAQAcdO3DqFywFOcW94fAE6oQFrzMEXELgUKsiSPMmUXMmWfMmYnMmavMmc3Mme/MmgHMqiPMqkXMqmfMqonMoGEQgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of significant changes in peritoneal transport rates - increased D/P creatinine, decreased D/Do glucose - characteristic of rapid transport in patients on maintenance peritoneal dialysis. Conversion to slower transport was much less common - eight percent for creatinine and 15 percent for glucose at two years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Blake, PG, Abraham, G, Somolosk, et al, Adv Perit Dial 1989; 5:3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_53_26461=[""].join("\n");
var outline_f25_53_26461=null;
var title_f25_53_26462="Contents: Lipid disorders";
var content_f25_53_26462=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lipid disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lipid disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31222\">",
"           Measurement of serum lipids and lipoproteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17015\">",
"           Effects of exercise on lipoproteins and hemostatic factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18149\">",
"           Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/54/29546\">",
"           Lipid abnormalities after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/45/18138\">",
"           Lipoprotein classification; metabolism; and role in atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43621\">",
"           Secondary causes of dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10613\">",
"           ATP III guidelines for treatment of high blood cholesterol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44659\">",
"           Antihypertensive drugs and lipids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35578\">",
"           Approach to the patient with hypertriglyceridemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33656\">",
"           Cholesterol lowering after an acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/50/19240\">",
"           Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43626\">",
"           Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19111\">",
"           Compliance with lipid altering medications and recommended lifestyle changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/34/2601\">",
"           Dietary fat",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/2/39978\">",
"           HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/3002\">",
"           Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28474\">",
"           Lipid lowering with diet or dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/14/42217\">",
"           Lipid lowering with drugs other than statins and fibrates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7800\">",
"           Lipid lowering with fibric acid derivatives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40248\">",
"           Lipoprotein(a) and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/2/32\">",
"           Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24453\">",
"           Statin therapy in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/35/32314\">",
"           Statins: Actions, side effects, and administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/63/10230\">",
"           Statins: Possible noncardiovascular benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10329\">",
"           Treatment of drug-resistant hypercholesterolemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/32/14856\">",
"           Treatment of lipids (including hypercholesterolemia) in primary prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/32/26122\">",
"           Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-894F7306AA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_53_26462=[""].join("\n");
var outline_f25_53_26462=null;
var title_f25_53_26463="Contents: Primary care oncology";
var content_f25_53_26463=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care oncology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care oncology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Brain tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/17/36117\">",
"           Classification of gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/3/25657\">",
"           Clinical presentation and diagnosis of brain tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Breast cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/4/37961\">",
"           Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/40/20106\">",
"           Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/10/20649\">",
"           Breast development and morphology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39386\">",
"           Breast reconstruction in women with breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/49/10009\">",
"           Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32249\">",
"           Genetic testing for hereditary breast and ovarian cancer syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42825\">",
"           Management of the regional lymph nodes in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/46/19177\">",
"           Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/14\">",
"           Paget disease of the breast",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/7/11385\">",
"           Role of radiation therapy in breast conservation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41754\">",
"           Screening for breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7354\">",
"           Systemic treatment for metastatic breast cancer: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/45/24278\">",
"           Tumor node metastasis (TNM) staging classification for breast cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cancer pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7077\">",
"           Assessment of cancer pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/7/30842\">",
"           Cancer pain management with opioids: Optimizing analgesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9290\">",
"           Cancer pain management with opioids: Prevention and management of side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39066\">",
"           Cancer pain management: Adjuvant analgesics (coanalgesics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/43/43704\">",
"           Cancer pain management: General principles and risk management for patients receiving opioids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4488\">",
"           Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21146\">",
"           Overview of cancer pain syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33924\">",
"           Radiation therapy for the management of painful bone metastases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39894\">",
"           Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39210\">",
"           Prevention and treatment of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32746\">",
"           Approach to the patient with colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2634\">",
"           Association between Helicobacter pylori infection and gastrointestinal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11850\">",
"           Clinical features, diagnosis, and staging of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38762\">",
"           Clinical features, staging, and treatment of anal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17946\">",
"           Clinical manifestations, diagnosis, and staging of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7898\">",
"           Diagnosis and staging of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18938\">",
"           Epidemiology, clinical features, and types of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43881\">",
"           Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16618\">",
"           Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29783\">",
"           Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43063\">",
"           Overview of treatment approaches for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/12/8391\">",
"           Pathogenesis of Barrett's esophagus and its malignant transformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/34/41514\">",
"           Pathology and prognostic determinants of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/9/3224\">",
"           Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6983\">",
"           Screening and prevention of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35337\">",
"           Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35336\">",
"           Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31849\">",
"           Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25978\">",
"           Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17224\">",
"           Epithelial ovarian cancer: Pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/36/16969\">",
"           Initial approach to low-risk clinically localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41001\">",
"           Measurement of prostate specific antigen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/31/5624\">",
"           Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/45/9943\">",
"           Posttreatment follow-up for men with testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/52/31562\">",
"           Risk factors for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34202\">",
"           Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10474\">",
"           Screening for ovarian cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lung cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12298\">",
"           Cigarette smoking and other risk factors for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44537\">",
"           Diagnostic evaluation and management of the solitary pulmonary nodule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16282\">",
"           Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/35/42552\">",
"           Pathobiology and staging of small cell carcinoma of the lung",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10072\">",
"           Women and lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28121\">",
"           Adenocarcinoma of unknown primary site",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/24/42378\">",
"           Cancer prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/34/17960\">",
"           Clinical features and pathogenesis of cancer cachexia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/26/14758\">",
"           Overview of the classification and management of cancers of unknown primary site",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39015\">",
"           Survival estimates in advanced cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/38/3690\">",
"           Various rehabilitation issues in patients treated for cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic cancers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/18/40232\">",
"           Vestibular schwannoma (acoustic neuroma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18073\">",
"           Primary prevention of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16650\">",
"           Screening and early detection of melanoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Testicular cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41720\">",
"           Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2457\">",
"           Epidemiology of and risk factors for testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24852\">",
"           Risk stratification of metastatic testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/58/38822\">",
"           Serum tumor markers in testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/49/20250\">",
"           Treatment-related toxicity in men with testicular germ cell tumors",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-35C52201BB-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_53_26463=[""].join("\n");
var outline_f25_53_26463=null;
